

I.S.Mu.L.T. Hyaluronic acid injections in musculoskeletal disorders guidelines

Antonio Frizziero¹
 Filippo Vittadini²
 Francesco Oliva³
 Giovanni Abatangelo¹¹
 Serenella Bacciu⁸
 Anna Berardi⁴
 Michela Bossa⁸
 Roberto Buda⁷
 Daniela Buonocore¹²
 Filippo Calderazzi⁵
 Antonio Carolla⁵
 Francesco Ceccarelli⁵
 Cosimo Costantino⁶
 Maurizia Dossena¹²
 Cesare Faldini⁷
 Paolo Finotti¹
 Calogero Foti⁸
 Luigi Frizziero¹³
 Stefano Galletti¹⁴
 Giuseppe Gasparre¹
 Alessio Gaii Via¹⁵
 Asmaa Mahmoud⁸
 Stefano Masiero¹
 Giovanni Merolla⁸
 Alberto Migliore¹⁶
 Simone Natali⁷
 Simone Nicoletti¹⁷
 Antonello Padolino⁸
 Leonardo Pellicciari⁸
 Eleonora Piccirilli³
 Eleonora Pintus⁷
 Giuseppe Porcellini⁸
 Davide Romiti⁶
 Marco Terreni¹²
 Alessandro Valent¹⁸
 Francesca Vannini⁷
 Manuela Verri¹²
 Antonella Vertuccio¹⁰
 Marco Vetrano¹⁰
 Maria Chiara Vulpiani²⁰
 Nicola Maffulli¹⁸

¹ Department of Physical and Rehabilitation Medicine, University of Padova, Padova, Italy

² Venezia FC Medical Staff, Venice, Italy - Department of Physical and Rehabilitation Medicine, Casa Di Cura Giovanni XXIII, Monastier di Treviso, Italy

³ Department of Orthopaedics and Traumatology, University of Rome "Tor Vergata", Rome, Italy

⁴ UOC of Immunohaematology and Transfusion Medicine, Santo Spirito Hospital, Pescara, Italy

⁵ Orthopaedic and Trauma Department, Parma University, Parma, Italy

⁶ Rehabilitation Medicine, Department of Clinical and Experimental Medicine, Parma University Hospital, Parma, Italy

⁷ Rizzoli Orthopaedic Institute, University of Bologna, Bologna, Italy

⁸ Physical and Rehabilitation Medicine, University of Rome "Tor Vergata", Rome, Italy

⁹ Shoulder and Elbow Unit, "D. Cervesi" Hospital, Cattolica, Italy

¹⁰ Physical Medicine and Rehabilitation Unit, Sant'Andrea Hospital, "Sapienza" University of Rome, Rome, Italy

¹¹ Department of Histology, Microbiology and Medical Biotechnology, University of Padova, Padova, Italy

¹² Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, Pavia, Italy

¹³ Department of Rheumatology, Villa Toniolo Hospital, Bologna, Italy

¹⁴ Musculoskeletal ultrasound School, Italian Society for Ultrasound in Medicine and Biology (SIUMB), Bologna, Italy

¹⁵ Department of Orthopaedics and Traumatology, Hip Surgery Center, IRCCS Policlinico San Donato, San Donato Milanese (MI), Italy

¹⁶ Unit of Rheumatology, "Ospedale S. Pietro FBF", Rome, Italy

¹⁷ Orthopaedic and Trauma Department, San Jacopo Hospital, Pistoia, Italy

¹⁸ Fisioclinics Formigine Clinic, Modena, Italy

¹⁹ Department of Musculoskeletal Disorders, Faculty of Medicine and Surgery, University of Salerno, Baronissi, Salerno, Italy; Centre for Sports and Exercise Medicine, Barts and The London School of Medicine and Dentistry, Mile End Hospital, London, UK

Corresponding author:

Filippo Vittadini
 Venezia FC Medical Staff
 Department of Physical and Rehabilitation Medicine,
 Casa Di Cura Giovanni XXIII, Monastier di Treviso, Italy
 E-mail: filippo.vittadini@gmail.com

Summary

Intra-articular and peri-articular hyaluronic acid (HA) injections are widely used to treat several musculoskeletal pathologies. Although clinical

outcomes are often positive for different conditions, an holistic consensus on this topic is still lacking. Our work is divided in two main sessions: in the first section we analyzed the preclinical bases for HA treatment in musculoskeletal pathologies, while in the second part we discussed the evidence on the use of HA injections in each district of musculoskeletal system. The aim of this work is to provide to the physician a feasible guideline rapidly to consult in the clinical practice.

Level of evidence: Ia.

Approach to guidelines

These recommendations developed through a process of systematic review of the literature and expert opinion, to be used to improve the quality of care and rationalize the use of resources.

Clinical decisions on individual patients require the application of the recommendations, based on the best scientific evidence and clinical experience of the physician.

Methodology

The Authors were divided into four groups:

- a coordinator conceived and organized the work and the groups, and selected the most important questions on the topic at hand;
- a overseeing group controlled the development of the work and discussed the recommendations;
- the group of the experts individually received a question and developed the answers according to the rules of EBM, when it was possible;
- the group of preparation and evaluation of literature drew up the text and assisted the group of experts in evaluating the literature.

Methods and criteria of study selection

For the research were consulted the following databases:

- PubMed
- Embase
- Google Scholar
- Cochrane Library.

Randomized controlled trials (RCTs); systematic reviews; to follow if missing the first two, the other levels of evidence. The literature is updated at December, 2016.

Level of evidence

Level of evidence

Criteria for analysis and inclusion

- I Meta-analyses and systematic reviews of randomized controlled trials (RCTs) of high quality, or

RCTs with minimum or low risk of bias. Systematic reviews of high quality relative to cohort studies or case-control.

- II Cohort studies or randomized case-control high quality, with minimal risk of confounding or bias and with high or discrete probability of causation.
- III Case-control studies and retrospective comparison of well-conducted with reasonable probability of causation.
- IV Non-analytic studies as case series or individual cases.

Level of recommendation

Level of recommendation *Criteria for analysis*

- A Supported by at least two studies of level Ib or from a review level Ia ("it was shown").
- B Supported by at least two independent studies of level II or extrapolations from studies of level I ("it is possible").
- C Not supported by adequate studies of level I or II ("indications").
- D Indications of experts ("there is no evidence").

Hyaluronic acid

Hyaluronic acid (HA) is a non-sulfated glycosaminoglycan (GAG), formed by repetitive units of glucuronic acid and N-acetyl glucosamine, widely express in the extracellular matrix (ECM) to confer protection, shape and mechanical support to cells and tissues. HA for its composition and expression is a key-component of cartilage and tendon structures, where it contributes to viscoelastic properties¹⁻⁵. Stiff segments, linked by flexible domains to confer a super-helix, form the 50-70% of the molecule⁶. Therefore, viscoelastic properties of HA solutions can therefore be explained by the development of a dynamic three-dimensional network formed by transient associations between stiff segments⁷⁻⁹.

However, the importance of this molecule depends in part by its structure and hygroscopic properties, in part by the interaction with a large number of surface and intracellular receptors: CD44 glycoproteins, ICAM-1 and RHAMM, HARE, and intracellular proteins binding the hyaluronic acid CDC37, RHAMM/IHABP, P-32 and IHABP^{4,10-12}.

Injection techniques and good clinical practice

Intra-articular and peri-articular procedures should be accomplished in adequate clinical settings following evidence based medical recommendations and a point-to-point procedure¹³⁻¹⁵:

- collect history and clinical examination;
- obtain oral/written informed consent;
- prepare the equipment;
- prepare the patient;
- disinfect the skin before and after the injection;
- program follow-up evaluation.

The equipment required is:

- gloves/sterile gloves;
- sterile swabs and sterile draps;
- prepacked sterile needles and syringes;

- disinfectant (iodopovidone/chlorexidhine);
- synovial fluid collection bottles;
- sterile ultrasound kit (only for US-guided injection);
- emergency kit^{16,17}.

The choice of the right needle is mandatory, considering the characteristics of the target joint. A needle of 21 gauge should be preferred in large joints as the shoulder or the knee, while 23-25 gauge needles are indicated in small joints¹³. Deep joints as the hip required the adoption of spinal needles (length of 3,5 inches; 8-9 centimeters)¹⁸.

Clinicians should identify any possible contraindications to the procedure. Absolute contraindications are: systemic infections and bacteremia, articular infections, skin lesions in the area, osteomyelitis, septic arthritis, unstable coagulopathy and severe thrombocytopenia, allergy (hypersensitivity) to any of the components and pregnancy. Injections procedures should be carefully performed in patients that use anticoagulants or other medications that alter INR. Injections should be avoided in patients with prolonged bleeding time or platelet count < 100 000/ μ l¹⁸.

Generally, adverse effects are local and well-tolerated. Common local side effects are redness and pain in the site of injection (<72 hours after injection). Septic arthritis is rare (1:1000), while some cases of calcium pyrophosphate dihydrate crystal deposition disease (CPPD) are documented to be exacerbated by hyaluronic acid injections. Cross-linked products were related to severe acute inflammatory reaction (SAIR), a pseudo-septic condition probably related to immune-response mechanisms^{13,19,20}.

Key points

- The injection should always be performed respecting sterile standardized procedures. It is mandatory to carefully disinfect the area preferring chlorhexidine preparations, mixtures of chlorhexidine gluconate and ethyl alcohol, iodopovidone solutions and analogs.
- The choice of the needle should consider the type of injection, the characteristics of the target joint and patient.
- Injection could be preceded by arthrocentesis, which is helpful to the diagnosis of underlying pathological process in selected patients.
- Patients should observe a waiting period of 20-30 minutes in an outpatient facility after the injection.

KEY WORDS: *musculoskeletal injection, guidelines, hyaluronic acid, principles, accuracy, disinfection.*

Hyaluronic acid properties in joint disorders and osteoarthritis

It was demonstrated that HA should protect articular environment through several mechanisms of action: anti-inflammatory effect, chondroprotection, analgesic effect, subchondral bone protection and increased production of endogenous HA.

Anti-inflammatory effect

Several *in vitro* and *in vivo* studies suggest that anti-inflammatory action is determined by the reduction of the principal mediators of inflammation as IL-1²¹, TNF- α ²², IL-6, IL-8²³ and prostaglandin E2 (PGE2)^{24,25}. Interaction with CD44 leads to decrease in IL-1 β and metalloproteinases (MMPs) in cartilage and synovial fluid^{21,26}, decrease in PGE2 expression in synovial fluid²⁷, increase of TIMP-1 production and inhibition of anti-inflammatory response²⁸.

New products as HYADD-4 (Hymovis®, Fidia Farmaceutici SpA, Abano Terme, Italy) and H/L-HA (Sinovial HL®, IBSA SA, Switzerland) may determine a better anti-inflammatory response^{29,30}.

Chondroprotection

Chondroprotection is determined by the reduction of chondrocyte apoptosis and by the increase in chondrocyte proliferation and viability, with the consequent increase in the production of ECM components (GAGs and PGs)³¹⁻³⁴. Increased viability and proliferation is due in part to the down-regulation of proteolytic enzymes as MMPs and aggrecanases (ADAMTS)³⁵⁻³⁸.

Anti-apoptotic effects is linked to different mechanisms as Fas/Fas-ligand and mitochondrial function³⁹⁻⁴⁴.

Analgesic effect

HA seems to exert analgesic effects through different mechanisms. In part, this action should be explained by the modulation of nociception due to down-regulation of main inflammatory mediators, as PGE2 and bradykinin⁴⁵⁻⁴⁹. Furthermore, viscoelastic properties of HA should reduce mechanical forces transmitted to nociceptive endings⁵⁰⁻⁵². Recent findings evidenced that HA can induce activation of k-opioid receptor (KOP), suggesting other possible pathways of analgesic activity⁵³.

Subchondral bone protection

HA can directly reduce osteoblast expression of MMP-13 and IL-1 β induced expression of MMP-3, ADAMTS-4 and ADAMTS-5^{54,55}. HA should also act on osteoclasts enhancing expression of osteoprotegerin (OPG) and inhibiting RANK-ligand^{56,57}.

Production of endogenous HA

HA injections determine a concentration dependent increase of endogenous HA production⁵⁷. Endogenous HA concentration was found to be increased also at 3 and 6 months post-injection⁵⁸⁻⁶¹.

Keypoints

- HA intra-articular injections could determine disease-modifying effects through several mechanisms of action: anti-inflammatory effect, chondroprotection, analgesic effect, subchondral bone protection and increased production of endogenous HA.
- Currently it is not clear whether any formulation is

- superior as disease-modifying molecule.
- New formulations (HYADD-4, H/L-HA) may determine a greater anti-inflammatory effect.

Level of recommendation: A.

KEY WORDS: *hyaluronic acid, chondroprotection, cartilage, subchondral bone, anti-inflammatory, intra-articular, osteoarthritis, chondrocyte, osteoblast.*

Hyaluronic acid properties in soft tissues: tendons, ligaments and bursas

Tendons

HA should enhance tenocyte viability and proliferation and reduce collagen III production, while it is not well established if HA may determine increase in collagen I production⁶²⁻⁶⁴.

Keypoints

- In Achilles tendinopathy, HA injections stimulate healing process, reducing adhesion formation and regulating the expression of vascular endothelial growth factor (VEGF) and type IV collagen⁶⁵.
- In rotator cuff diseases, HA injections exert mechanical (anti-adhesion) and biological effects (reduction of PGE2, C4S, IL-1 and modulation of leukocytes migration)⁶⁶.
- In patellar tendinopathy, HA injections associated to rest should increase anabolic metabolism of tenocytes^{67,68}.

Level of recommendation: B.

Ligaments

Actually, there are no evidences that support the use of HA injections in ligament pathologies or a direct action of HA on ligament structure. Some trials suggest the possible role of early HA injection after ACL surgery⁶⁹.

Level of recommendation: D.

Bursas

Some studies have recently investigated the possible role of US-guided injections importance in different bursas, including the subacromial bursa⁷⁰; however, it is not univocally known whether HA could improve the composition of the synovial fluid of bursa pathologies⁷¹.

Level of recommendation: D.

Hyaluronic acid in shoulder disorders

Shoulder pain is common in general population⁷² and could be referred to rotator cuff tendinopathy, glenohumeral osteoarthritis or acromionclavicular osteoarthritis^{73,74}. Capsulitis should also be considered and it could be idiopathic or secondary to intraarticular and extra-articular pathologies. The use of NSAIDs is considered the first line treatment, but injection procedures should be indicated in non-responders patients.

Glenohumeral injections

Intra-articular injections in glenohumeral joint are widely used in clinical practice and several studies promote the efficacy in short and medium term⁷⁵⁻⁸⁴ (Tab. I). Intra-articular injections in glenohumeral joint are proposed for different pathologies, as osteoarthritis and rotator cuff pathology and frozen shoulder.

Level of recommendation: A.

Adhesive capsulitis

Several Authors evaluated the role of HA injections in adhesive capsulitis, but in many studies patients affected by AC represent a subgroup^{75,84,85-88}. Injection therapy should be considered in a multimodal approach that includes capsular stretching and exercise therapy.

Level of recommendation: B.

Subacromial injections

Five studies were selected (Tab. II)⁸⁹⁻⁹³. Subacromial injections are proposed in rotator cuff pathology or subacromial space syndrome. This procedure should be ultrasound-guided to permit sufficient accuracy.

Level of recommendation: A.

Key points

- Intra-articular injections in glenohumeral joint should determine a great efficacy in osteoarthritis in short and medium term, while the procedure is not superior to other therapies in ROM improvement in adhesive capsulitis.
- Ultrasound-guided subacromial injections improve pain and function in rotator cuff pathology.
- There is lack of evidence about the possible role of HA in acromion-clavicular disorders.

KEY WORDS: *hyaluronic acid, tendon, tendinopathy, ligaments, extra-articular.*

Hyaluronic acid in elbow disorders

Lateral epicondylitis

Lateral elbow pain could be reported in several pathologies as chondromatosis, chondral lesions, intra-articular loose bodies, elbow instability or posterior interosseus nerve syndrome.

Thus, correct differential diagnosis is mandatory to achieve good clinical outcomes.

Several conservative modalities were described to treat lateral tennis elbow syndrome, while surgery is indicated only in refractory cases.

Only one RCT and few level IV trials investigated the possible role of HA in epicondylitis (Tab. III)^{68,94,95}.

These studies are heterogeneous for methodologies neither use US-guidance.

Level of recommendation: B.

Elbow osteoarthritis

Elbow is not a common site of osteoarthritis, characterized by cartilage loss, osteophytes formation and intra-articular loose bodies.

The low prevalence should partially explain that the

Table I. Selected studies on intra-articular glenohumeral injections.

Author and year	Study design	Protocol/pathology	Follow-up (weeks)	Outcome measures	Results	Level of evidence
Blaine et al. 2008 ⁷⁵	RCT	5 injections of Hyalgan® (221 patients) 3 injections of Hyalgan® + 2 injections of placebo (218 patients) 5 injections of placebo (221 patients) Chronic shoulder pain	26	VAS pain scale	Pain reduction in treated groups until 26 weeks of follow-up	I
Kwon et al. 2013 ⁷⁶	RCT	3 injections of Supartz® (150 patients) 3 injections of placebo (150 patients) Gleno-humeral osteoarthritis	26	VAS pain scale, responder percentages in OMER-ACT-OARSI	Significant improvement in pain and function for treated group compared to control group at all endpoints	I
Merolla et al. 2011 ⁷⁷	Retrospective controlled	3 injections of Synvisc® (51 patients) 3 injections of 6-methylprednisone acetate (33 patients) Gleno-humeral osteoarthritis	24	VAS, Constant-Murley	Significant improvement in pain and function for treated group compared to control group at all endpoints (p<0,05)	III
Ozgen et al. 2012 ⁷⁸	Perspective randomized	3 injections of Synvisc® (12 patients) Standard rehabilitative treatment (12 patients) Supraspinatus tendinopathy	4 years	VAS, ROM, SASES score	Significant improvement in both groups (p<0,001) without differences	II
Park et al. 2013 ⁸⁴	Perspective randomized	2 injections with ND device (45 patients) 2 injections with ND corticosteroid (45 patients) Adhesive capsulitis	6	VNS, ROM	Significant improvement in both groups for pain, statistically better improvement in external rotation for HA (p<0,001)	II
Rovetta & Monteforte 1998 ⁸⁹	Perspective randomized	8 injections of Hyalgan® + triamcinolone acetonide + exercise (15 patients) 8 injections of triamcinolone acetonide + exercise (15 patients) Adhesive capsulitis	24	VAS, ROM	Significant improvement in pain and function for treated group compared to controls at all endpoints (p<0,001)	II
Hsieh et al. 2012 ⁹⁰	RCT	3 injections with ND device (35 patients) Physical therapies (35 patients) Adhesive capsulitis	12	SPADI, ROM, SF-36	Significant improvement in both groups (p<0,001) without differences	I

role of HA is not well established and limited in secondary osteoarthritis. Only two case series investigated HA in elbow osteoarthritis (Tab. IV)^{96,97}.

Level of recommendation: C.

Keypoints

- Low grade evidences support HA injections in elbow tendinopathies.

Table II. Selected studies of subacromial space injections

Author and year	Study design	Protocol/pathology	Follow-up (weeks)	Outcome measures	Results	Level of evidence
Meloni et al. 2008 ⁹¹	RCT	5 injections of Hyalgan® (28 patients) 5 injections of placebo (28 patients) Supraspinatus tendinopathy	48	VAS pain scale	Significant improvement in pain and function for treated group compared to controls at all endpoints (p<0,001)	I
Chou et al. 2010 ⁹²	RCT	5 injections of Artz® (25 patients) 5 injections of placebo (26 patients) Gleno-humeral osteoarthritis	2 years	VAS, Constant-Murley	Significant improvement in pain and function for treated group compared to controls at all endpoints (p<0,001)	I
Tagliafico et al. 2011 ⁹³	Perspective, open-label	2 injections of high molecular weight HA ND (33 patients) Group that refused infiltrative therapy (60 patients) Massive rotator cuff lesion combined to advanced gleno-humeral osteoarthritis	24	VAS, Constant-Murley	Significant improvement in pain and function for treated group at 1, 2, 3 and 4 months follow-up, without statistical differences compared to controls at 6 months	III
Moghtaderi et al. 2013 ²⁹	RCT	3 injections of Fermatron® (20 patients) 3 injections of placebo (20 patients) Rotator cuff tendinopathy	12	VAS, Constant-Murley	Significant improvement in pain and function for treated group compared to controls (p<0,001)	I
Merolla et al. 2013 ³⁰	Perspective randomized	2 injections of SportVis® (25 patients) Standard rehabilitative treatment (23 patients) Supraspinatus tendinopathy	12	Oxford Shoulder Score, Constant-Murley Score	Significant improvement in pain and function for treated group from 2 to 12 weeks and in CS at 4 and 12 weeks compared to controls	II

- There are not sufficient evidences to recommend or avoid HA in primary and secondary elbow osteoarthritis.
- No adverse effects were observed with HA injections in patients affected by elbow pathologies.

KEY WORDS: hyaluronic acid, lateral epicondylitis, elbow osteoarthritis, elbow stiffness, elbow injection of hyaluronic acid, medial epicondylitis, hyaluronan elbow, sodium hyaluronate elbow.

Hyaluronic acid in hip disorders

Only few randomized controlled trials investigated the use of intra-articular injections of HA in hip osteoarthritis⁹⁸⁻¹⁰⁵ and they are very heterogeneous for methodologies and type of HA used (Tab. V). In a recent systematic review and meta-analysis, Piccirilli et al. concluded that HA represents a valid conservative therapeutic option for hip pathology, al-

though there is lack of uniformity regarding choice of HA type, timing and number of injections¹⁰⁶.

Level of recommendation: B.

Keypoints

- Viscosupplementation is the best conservative treatment for osteoarthritis and it acts on pain reduction.
- Actually there is no uniformity regarding number or timing of infiltrative procedures.
- Ultrasound-guided infiltrative procedure is the best approach in terms of safety.
- In absence of comparative RCTs, no significant outcome differences seem to occur with different molecular weight HA formulations.
- Effectiveness on symptoms is only demonstrated in mild to moderate osteoarthritis, while infiltrative therapy is not indicated for severe forms of pathology.

Table III. Selected studies on epicondylitis.

Author and year	Study design	Protocol/pathology	Follow-up (weeks)	Outcome measures	Results	Level of evidence
Petrella et al. 2010 ⁹⁴	RCT	2 injections of HA ND (165 patients) 2 injections of placebo (166 patients)	48	VAS pain scale, gripping force with dynamometer, return to sport	Significant improvement in pain and function for treated group compared to controls at all endpoints (p<0,001)	I
Kumai et al. 2014 ⁶⁸	Perspective, non randomized	1 injection of Suvenyl® (16 patients) Epicondylitis	1	VAS	Improvement ≥2 cm in VAS scale in 10 patients (62,5%)	IV
Tosun et al. 2015 ⁹⁵	RCT	1 injection of laluril® (25 patients) 1 injection of triamcinolone acetonide (32 patients) Epicondylitis	12	VAS, PRTEE	Significant improvement in pain and function for HA+CS group at 3 months and in pain at 6 months compared to CS group	II

Table IV. Selected studies on elbow osteoarthritis.

Author and year	Study design	Protocol/pathology	Follow-up (weeks)	Outcome measures	Results	Level of evidence
Van Brakel & Eygendaal 2006 ⁹⁶	Case series	3 injections of Fermathron® (18 patients -19 joints) Post-thraumatic osteoarthritis	24	VAS, EFA score, Broberg-Morrey Functional Rating Index	Slight non-significant improvement in pain and rigidity at 3 months	IV
Pederzini et al. 2013 ⁹⁷	Case series	1 injection of Hyaloglide®+ arthrolysis (17 patients) Arthroscopic arthrolysis (19 patients) Post-thraumatic osteoarthritis	10	VAS, ROM, Liverpool elbow score (LES)	Higher percentage of patients with pain reduction in HA group (p=0,0419), significant reduction in pain intensity in both groups (p<0,0001)	IV

KEY WORDS: hyaluronic acid, hip injections, hip osteoarthritis, hip diseases.

Hyaluronic acid in knee disorders

Knee is the most studied application of HA injections and a common site of pathology, representing over 45% of total cases of symptomatic osteoarthritis. Several high-quality meta-analyses and review of RCTs were performed (Tab. VI).

Effects on symptoms

Intra-articular injections of HA lead to symptom relief comparable or superior to traditional treatments, such as intra-articular corticosteroids, NSAIDs, analgesics, lifestyle changes and physical exercise¹⁰⁷⁻¹¹².

Level of recommendation: A.

Structural effects

Different studies have shown that the use of HA in knee osteoarthritis leads to structural improvements, including reduction of grade and extension of cartilage lesions, accompanied by decrease in synovial fluid inflammation, improvement in quantity and density of chondrocytes, increase in synovial repair processes¹¹³⁻¹¹⁶.

Level of recommendation: A.

Effects on delay of prosthetic replacement surgery

Even if only few studies have been conducted on this topic, those carried out agree that repeated treat-

Table V. Selected studies on hip osteoarthritis.

Author and year	Study design	Protocol/pathology	Follow-up (weeks)	Outcome measures	Results	Level of evidence
Tikiz et al. 2005 ⁹⁸	RCT	3 injections of Synvisc® (25 patients, 32 hips) 3 injections of Ostenil® (18 patients, 24 hips)	24	VAS, WOMAC, Lequesne	Both treatments are effective without statistical differences	I
		Fluoroscopic guide				
Qvistgaard et al. 2006 ⁹⁹	RCT	3 injections of Hyalgan® (33 patients) 3 injections of placebo (36 patients) 1 injection of Depo-Medrol®+ 2 sham injections (32 patients)	12	VAS scale during walk	Significant pain reduction in CS group compared to placebo and HA at 14 and 28 days	I
Van den Bekerom et al. 2008 ¹⁰⁰	Perspective, non randomized	1 injection of Adant® (91 patients) 1 injection of Synocrom® (20 patients) 1 injection of Synvisc® (15 patients)	6	VAS, Harris Hip Score	Significant improvement in pain and function for Adant e Synocrom groups	III
		Fluoroscopic guide				
Richette et al. 2009 ¹⁰¹	RCT	1 injection of Adant® (42 patients) 1 injection of placebo (43 patients)	12	VAS	No significant differences between groups	I
		Fluoroscopic guide				
Migliore et al. 2009 ¹⁰²	RCT	2 injections of Hyalubrix® (22 patients) 2 injections of mepivacaine (20 patients)	12	VAS, Lequesne	Significant improvement in pain (p<0,05) and Lequesne (p<0,001) for HA group at all follow-up	I
		Ultrasound guide				
Spitzer et al. 2010 ¹⁰³	RCT	3 injections of Synvisc® (150 patients) 2 injections of metilprednisolone (155 patients)	26	WOMAC	HA is better than CS in advanced stages of pathology, same effectiveness in less advanced stages	I
		Fluoroscopic guide				
Atchia et al. 2011 ¹⁰⁴	Perspective, randomized	1 injection of Durolane® (19 patients) 1 injection di placebo (19 patients) 1 injection of corticosteroid (20 patients) Standard care (20 patients)	8	NRS, WOMAC	Significant improvement in pain and function for CS group	II
		Fluoroscopic guide				
Battaglia et al. 2013 ¹⁰⁵	RCT	3 injections of PRP (50 patients) 3 injections of Hyalubrix® (50 patients)	52	VAS, Harris Hip Score	Significant improvement in both groups (p<0,005) without differences at all follow-up	I
		Ultrasound guide				

ments with HA infiltrations are effective in delaying total knee replacement surgery¹¹⁷⁻¹²⁰.

Level of recommendation: B.

Table VI. Selected studies on knee.

Author and year	Study design	Number of cases	Clinical evaluation	Results	Level of evidence
Day et al. 2004 ¹⁰⁸	Multicentric, randomized, double blind	240 patients	6, 10, 14, 18 weeks VAS, WOMAC	Pain and articular stiffness reduction	I
Bannuru et al. 2011 ¹⁰⁹	Review of RCTs	54 studies 7545 patients	4, 8, 12, 16, 20, 24 weeks WOMAC Meta-analysis	Maximum pain reduction at 8 weeks	I
Trigkilidas & Anand 2013 ¹¹⁰	Review of RCTs	14 studies 2289 patients	VAS, WOMAC	Maximum pain reduction at 6-8 weeks	I
Strand et al. 2015 ¹¹¹	Review of RCTs	29 studies 4866 patients	From 4 to 13 and from 14 to 26 weeks Meta-analysis	Improvement in pain and function between 4 and 26 weeks	I
Waddell 2006 ¹⁰⁷	Retrospective study	1158 patients	VAS, severity e duration of adverse event	Slight to moderate adverse events lasting less than 48 hours	III
Pasquali et al. 2001 ¹¹⁵	RCT	99 patients	7, 14, 21, 28, 35, 60, 120, 180 days Blood and urine tests 180 days Arthroscopy and biopsy	Reduction of inflamed tissue, improvement of edema, increase in fibroblasts and collagen	I
Navarro-Sarabia et al. 2011 ¹¹⁴	Multicentric, randomized, with blind assessor	306 patients	6, 12, 24 e 48 months VAS, OARSI criteria, OMERACT-OARSI criteria	Ripetitive cycles of intra-articular HA lead to an improvement lasting til one year after the end of treatment	I
Turajane et al. 2009 ¹¹⁷	Perspective study	183 patients	54 months of follow-up Incidence of TKR	Incidence of TKR of 28,4%	II
Waddell & Joseph 2016 ¹¹⁸	Review	1342 patients	13 years of follow-up Incidence of TKR	TKR delayed of 3 years in 25% of patients TKR delayed of 7 years in 75% of patients	I

Keypoints

- Knee infiltration with HA is strongly recommended for pain relief and potential disease-modifying effects.
- Evidence is greater for patients with mild to moderate osteoarthritis (K/L II-III).
- HA injections may delay the need for prosthetic knee replacement.

KEY WORDS: *hyaluronic acid, molecular weight, knee, osteoarthritis, intra-articular injection, viscosupplementation, pain, tolerability, safety, meta-analysis, adverse events, total knee replacement.*

Hyaluronic acid in ankle disorders

Hyaluronic acid is frequently used to reduce symptoms in early stages of ankle osteoarthritis. Many methods of treatment have been proposed, but actually no precise algorithm has been defined. HA is typically used when first-level analgesics have not determined adequate benefit and it could represent an option to postpone surgery^{121,122}. In selected studies (7 studies; 5 RCTs) response to treat-

ment was moderate even a large share of the samples respond to the treatment (Tab. VII)¹²³⁻¹²⁹. It remains unclear which patients (age, degree of ankle osteoarthritis) may have greater improvement from HA injections and the number of injections to perform per patient.

Level of recommendation: B.

Keypoints

- HA is safe in ankle joint, although improvements in clinical scores appear to be slightly significant in higher quality trials.
- HA can be recommended in patients who respond inadequately to common analgesics.
- It remains unclear which patients may have greater improvement from HA injections and the number of injections to perform per patient.

KEY WORDS: *viscosupplementation, hyaluronic acid, ankle, arthritis.*

Hyaluronic acid in small joints

The role of HA in small joints is not well established yet. Few studies investigated HA injections trape-

Table VII. Selected studies on ankle pathologies

Author and year	Study design	Protocol	Follow-up (weeks)	Outcome measures	Results	Level of evidence
Salk et al. 2006 ¹²³	RCT	5 injections of Hyalgan® (10 patients) 5 injections of placebo (10 patients)	24	AOS	Significant improvement in I both groups (p<0,001)	
Cohen et al. 2008 ¹²⁴	RCT	5 injections of Hyalgan® (15 patients) 5 injections of placebo (15 patients)	12	AOS	Significant improvement in I HA group compared to control group	
Karatosun et al. 2008 ¹²⁵	Perspective, randomized	3 injections of Adant® (15 patients) Exercise (15 patients)	52	AOFAS score, VAS pain	Significant improvement in II both groups (p<0,001)	
Carpenter et al. 2008 ¹²⁶	Perspective, non randomized	Ankle arthroscopy + 3 injections of Synvisc® (14 patients) Ankle arthroscopy (12 patients)	48	10 points pain score scale	Significant pain reduction in comparison to controls	IV
Mei-Dan et al. 2012 ¹²⁷	RCT	3 injections of Euflexxa® (15 patients) 3 injections of PRP (14 patients)	28	AOFAS	Significant improvement in II both groups (p<0,001), higher for PRP group (p<0,05)	
DeGroot et al. 2012 ¹²⁸	RCT	1 injection of Supartz® (32 patients) 1 injection of placebo (32 patients)	12	AOFAS	Significant improvement in I both groups (p<0,001)	
Sun et al. 2014 ¹²⁹	RCT	1 injection of Hyalgan® + exercise (37 patients) 1 injection of botulinum toxin (38 patients)	24	AOS	Significant improvement in II both groups (p<0,001)	

ziometacarpal (TMC) and first metatarsophalangeal joint (MTPJ) OA, while other small joints were not studied.

Trapeziometacarpal joint osteoarthritis

Studies selected have heterogeneous protocols and only two RCTs were found (Tab. VIII)¹³⁰⁻¹³⁹. Although some studies demonstrate a significant decrease in pain at a medium-term follow-up, no significant superiority compared to corticosteroid or placebo is emerged. A volume of 0.3 cm³ injected for each injection seems to be ideal in order to reduce volume effect and post-injection pain¹⁵.

Level of recommendation: B.

First metatarsophalangeal joint osteoarthritis

Only few studies were conducted, while a high quality RCT showed that an intra-articular injection of hylan G-F 20 is no more effective than placebo in reducing symptoms in people with symptomatic first MTPJ OA (Tab. IX)¹⁴⁰⁻¹⁴².

Level of recommendation: C.

Keypoints

- In TMC OA a significant superiority compared to corticosteroids or placebo is not emerged, while HA seems to lead to higher improvements in long-

term follow-up.

- In first metatarsophalangeal joint, no high-quality study demonstrate the superiority of HA in comparison to corticosteroids or placebo.

KEY WORDS: *carpometacarpal joint, trapeziometacarpal, thumb, hallux rigidus, rhizarthrosis, metatarsophalangeal joint, golfer's toe and or viscosupplementation, hyaluronic acid, intra-articular injection.*

Hyaluronic acid in tendon and bursa

HA after flexor tendon repair surgery

HA has been widely used for topical application and injections after surgical repair of flexor tendons of the hand with the aim of promoting tendon sliding and preventing post-surgical adhesions. Many Authors have showed a lower granulation tissue formation with reduction of post-surgical adhesions, in part for reduced peritendinous inflammation. Four high-quality RCTs were found (Tab. X)¹⁴³⁻¹⁴⁶. HA products with higher molecular weight and longer half-life favor a greater permanence of HA into intrasynovial peritendinous space compared to native HA and low molecular weight formulations, ensuring greater clinical efficacy.

Level of recommendation: A.

Table VIII. Selected studies on injections in trapeziometacarpal joint.

Author and year	Study design	Protocol	Follow-up (weeks)	Outcome measures	Results	Level of evidence
Figen Ayhan et al. 2009 ¹³⁰	RCT	1 injection of Hylan G-F 20 (33 patients) 1 injection of saline solution (33 patients)	24	VAS, gripping force, Dreiser	Significant improvement in function ($p=0,001$), VAS pain ($p=0,002$), gripping force ($p=0,004$) for HA group	I
Salini et al. 2009 ¹³¹	Perspective non randomized	1 injection of HA 800-1200 kDa (18 patients)	4	VAS, FANS consumption, Dreiser, gripping force	Significant improvement in pain ($p<0,001$), function ($p<0,004$), force ($p<0,001$)	III
Di Sante et al. 2011 ¹³²	Perspective non randomized	3 weekly injections of HA ND (31 patients)	24	VAS, Duruöz Hand Index	Significant improvement only in pain at 1 and 3 months, but no improvement at 6 months nor in function	III
Frizziero et al. 2014 ¹³³	Retrospective non randomized	3 weekly injections of Hyalgan® (58 patients)	24	VAS, FANS consumption, gripping force	Significant improvement in pain ($p<0,001$) and reduced FANS consumption ($p<0,017$)	IV
Roux et al. 2007 ¹³⁴	Perspective randomized	Sinovial® 1 injection (14 patients) 2 injections (14 patients) 3 injections (14 patients)	12	VAS, Dreiser	Significant improvement in pain and function, without significant differences between groups	II
Heyworth et al. 2007 ¹³⁵	RCT	2 injections Synvisc® (20) 1 injection of placebo + 1 injection of betamethasone acetate (22 patients) 2 injections of placebo (18)	26	VAS, gripping force, DASH	No significant differences between groups, even if there is a positive trend for HA group after 4 weeks	I
Fuchs et al. 2005 ¹³⁶	Perspective randomized	3 injections of Ostenil Mini® (28 patients) 3 injections of triamcinolone acetonide (28 patients)	26	VAS, gripping force	Pain resolution, improvement in articular movement more lasting for HA group	II
Ingenoli et al. 2010 ¹³⁷	Case series	3 injections of Hyalubrix® (32 patients)	24	VAS, Dreiser, gripping force	Significant improvement in pain and local inflammation at short and medium term	IV
Bahadir et al. 2009 ¹³⁸	Perspective randomized	3 injections of Ostenil® (20 patients) 1 injection of triamcinolone acetonide (20 patients)	48	VAS, Duruöz Hand Index, gripping force	No significant differences between groups at all follow-up	II
Stahl et al. 2005 ¹³⁹	Perspective randomized	3 injections of Ostenil Mini® (26 patients) 3 injections of methyl-prednisolone (26 patients)	24	Pain, gripper, gripping force, Purdue Pegboard Test	Both treatment are effective, HA group shows higher improvement in gripping force and PPT	II

HA in trigger finger, entesopathies and bursitis

In two recent randomized clinical trials, ultrasound-guided infiltration of medium molecular weight HA has been proposed for the treatment of stenosing tenosynovitis of finger flexor tendons, with encouraging results¹⁴⁷⁻¹⁴⁸.

Evidence on clinical efficacy for HA in human insertional tendon disorders is limited at four studies, although results are promising^{68,94,149,150} (Tab. XI). HA injections have also been proposed for the treatment of bursitis. Actually only two prospective studies without a control group are available, respectively on

Table IX. Selected studies on first metatarsophalangeal joint injections.

Author and year	Study design	Protocol	Follow-up (weeks)	Outcome measures	Results	Level of evidence
Munteanu et al. 2011 ¹⁴⁰	RCT	1 injection of Hylan G-F 20 (75 patients) 1 injection of placebo (76 patients)	24	Foot Health Status Questionnaire	No significant differences between groups at all follow-up	I
Pons et al. 2007 ¹⁴¹	Perspective randomized	1 injection of Ostenil Mini® (20 joints) 1 injection of triamcinolone acetonide (20 joints)	11	VAS, AOFAS score	Significant difference in pain during movement and AOFAS score for HA group (p<0,05)	II
Petrella & Cogliano 2004 ¹⁴²	Perspective non randomized	8 injections of HA ND (47 patients)	16	VAS, tiptoe walking pain, ROM, global patient satisfaction	Significant improvement in all outcome measures	III

Table X. Selected studies on flexor tendons tendon pathology.

Author and year	Study design	Experimental groups	Protocol/pathology	Follow-up	Outcome measures	Results	Level of evidence
Wiig et al. 2014 ¹⁴³	RCT	PXL01 in (46 patients) (1,5-8,1 MDa, 15 mg/ml) Placebo (49 patients)	Injection between tendon and sheath and around sheath during surgery Surgical repair of hand areas I-II flexor tendons: adhesion prevention	Until 12 months	TAM, tip-bend distance, sensitivity, degree of tenolysis, gripping force	HA improves post-surgical recovery, with more pronounced difference 6 months after surgery	I
Özgenel & Etöz 2012 ¹⁴⁴	RCT	High molecular weight HA (11 patients) (1,0-2,9 MDa, 15 mg/ml) Placebo (11 patients)	1 injection during surgery, 2 injections at weekly intervals Hand area II flexor tendon injury: adhesion prevention	3 weeks, 3 months, long-term	TAM, TPM, functional outcome with Strickland grading system	No differences at 3 weeks, improvement in HA group at 3 months and long-term	I
Riccio et al. 2010 ¹⁴⁵	RCT	Hyaloglide® (26 patients) Standard surgical release (19 patients)	Application of Hyaloglide® along the exposed tendon surface and in digital canal Adhesions recurrence after tenolysis of flexor tendons in hand zone II	30-60-90-180 days after surgery	TAM, QuickDASH, working days lost after surgery	Better recovery of TAM and faster return to work and daily life activities in HA group	I
Hagberg et al. 1992 ¹⁴⁶	RCT	High molecular weight HA (4.0 Mda) Placebo (120 cases stratified in 6 classes)	Injection in tendon sheath after tenorrhaphia or tendon graft Adhesions after surgical repair of flexor tendons in hand zone II	4 months	TAM, extension deficit, DIPAM (active motion)	No significant effects of HA on recovery of TAM	I

Table XI. Selected studies on tendon and bursal pathologies.

Author and year	Study design	Experimental groups	Protocol/pathology	Follow-up	Outcome measures	Results	Level of evidence
Liu et al. 2015 ¹⁴⁷	RCT	Medium molecular weight HA (18 cases) (0,8-1,17 Mda) cortisone (19 cases)	1 US-guided injection of HA 1 US-guided injection of cortisone Trigger finger (stenosing tenosynovitis)	3 weeks, 3 months	Quinnell scale Michigan scale (MHQ), VAS, TAM, gripping force	Better outcomes for both groups, different trend for MHQ (progressive increase for HA; increase at 3 weeks, decrease at 3 months for steroid)	I
Callegari et al. 2011 ¹⁴⁸	RCT	Cortisone/lidocaine + medium molecular weight HA (0,8-1,2 MDa) (15 patients) Open surgical release (15 patients)	US-guided injection of cortisone/lidocaine and after 10 days of HA	3 weeks, 3-6-12 months	DASH, Satisfaction Visual Analog Scale (SVAS), VAS	Similar results between groups	I
Tosun et al. 2015 ¹⁴⁹	RCT	HA + chondroitin sulphate + prilocaine (25 patients) Triamcinolone + prilocaine (32 patients) No control group	Single injection of 1.6 mL in an area of about 2 cm ² immediately anterior and distal to the lateral epicondyle Lateral epicondylitis	3-6 months after injection	Pain and function with PatientRated Tennis Elbow Evaluation (PRTEE)	Pain and function significantly improved at 3 and 6 months in both groups, but better results for HA+CS group	II
Kumai et al. 2014 ⁶⁸	Pilot study	High molecular weight HA (2.7 Mda) (61 patients) No control group	Single injection of HMW-HA near affected tendon/insertion Entheopathy (epicondylitis, patellar tendinopathy, insertional Achilles tendinopathy, plantar fasciitis)	1 week after injection	Spontaneous pain (VAS), 5 categories of local symptoms, caused pain	VAS reduction for all infiltrated sites and improvement of local caused pain	IV
Muneta et al. 2012 ¹⁵⁰	Cohort study	- Low molecular weight HA+ lidocaine (50 patients)(9.0 Mda) No control group	Injection between posterior tendon surface and infrapatellar fat (patellar tendinopathy) or more painful point around tendon; repeated from 1 to 11 times spaced at least 1 week Patellar tendinopathy and anterior knee pain syndrome in athletes	6-88 months	Roles and Maudsley modified score (pain and practice of sport)	Slight increase in pain 1-2 days after injection, then improvement compared to previous condition. Most effective in patellar tendinopathy compared to other types of anterior knee pain	II

To be continued

Continue from **Table XI.**

Petrella et al. 2010 ⁹⁴	RCT	- HA (165 patients) (molecular weight not specified) - saline solution (166 patients)	2 weekly injections in subcutaneous and muscular tissue 1 cm from lateral epicondyle	7-14-30-90-365 days	VAS, gripping force, global satisfaction, return to ADL and sport	Better results in I HA group
Lateral epicondylitis						
Chen et al. 2014 ¹⁵²	Cohort study	High molecular weight HA(6000 kDa) (10 patients) Low molecular weight HA (500-730 kDa) (10 patients) No control group	3 intrabursal injections after aspiration with lateral access, on a weekly basis Knee suprapatellar bursitis	1-2-3-4 weeks after first injection	Difference in protein concentration in synovial fluid before and after injection	Similar results in II both groups
Chang et al. 2009 ¹⁵¹	Pilot study	Cortisone + medium molecular weight HA (22 patients)(940-1020 kDa) No control group	3 non-guided weekly injections with access at vertebral margin of the scapula between serratus anterior muscle and lateral thoracic wall Scapulothoracic bursitis	1-2-3 weeks and 3 months after first injection	VAS, Rubin scale	Pain reduction, IV no significant adverse events

scapulo-thoracic bursitis¹⁵¹ and on suprapatellar bursitis¹⁵²; both studies reported significant improvements and Authors seem to encourage the use of HA in such conditions.

Level of recommendation: C.

Keypoints

- HMW-HA into intrasynovial peritendinous space should be proposed after surgical repair of flexor tendons of the hand with the aim of preventing adhesions and optimize recovery of motility and function.
- Currently, the use of HA in insertional tendon disease, trigger finger and bursitis is not strongly supported by evidences, even reporting encouraging results without major side effects.

KEY WORDS: tendon, periarticular, tendinopathy and or hyaluronic acid, injection.

Combination therapy with HA

Association with corticosteroids

Several studies investigated combined therapy with corticosteroids in various pathologies, as knee osteoarthritis, stenosing tenosynovitis of fingers flexor tendons, internal derangement of temporomandibular joint, adhesive capsulitis and lateral epicondylitis (Tab. XII)^{89,148,153-157}. Despite the different indications and protocols, all these studies suggested the superiority of the therapeutic association in terms of efficacy (pain reduction) compared to the use of each treatment alone.

Level of recommendation: B.

Association with local anesthetics

In the selected studies HA and local anesthetics have been used in association to other drugs, so it is difficult to establish the clinical efficacy of this combined therapy, whether the outcome was favorable for combined treatment groups^{148,149,157}.

Level of recommendation: C.

Association with NSAIDs

Only two RCTs analyzed the association between HA and NSAIDs. Both demonstrated a superiority in terms of pain reduction for combined intra-articular therapy compared to HA alone in subjects suffering of knee OA^{158,159}.

Level of recommendation: C.

Association with PRP

A retrospective non-randomized clinical trial on patients affected by Kellgren-Lawrence grade III-IV knee OA showed better outcome for the group treated with association between HA and PRP compared to HA alone¹⁶⁰.

Level of recommendation: C.

Association with MSCs

A recent RCT showed an increased quality of articular cartilage tissue after associative treatment with HA and peripheral blood stem cells compared to HA alone in patients with chondral lesions of the knee¹⁶¹.

Level of recommendation: C.

Table XII. Selected studies on combination therapies.

Author and year	Study design	Population	Treatments	Type of HA	Type of cotherapy	Follow-up period	Level of evidence
Callegari et al. 2011 ¹⁴⁸	RCT	30 patients with stenosing tenosynovitis of fingers flexor tendons	2 groups: - corticosteroids + HA (group A) - open surgery (group B)	1 ml 0.8% of HA (Sinovial Mini)	Methylprednisolone acetate 40 mg/1 ml (Depo-medrol)	6 weeks, 3, 6, 12 months	II
De Campos et al. 2013 ¹⁵³	RCT	104 patients with gonarthrosis	2 groups: - 1 injection of HA (VS group); - 1 injection of HA + triamcinolone (VS+T group).	6 ml of Hyalan GF-20	1 ml/20 mg of triamcinolone hexacetonide	1, 4, 12, 24 weeks	I
Giombini et al. 2016 ¹⁶²	RCT	70 subjects with gonarthrosis	3 groups (1 injection/week for 5 weeks): - HA only (n = 23); - only O ² O ³ (n = 23); - HA+O ² O ³ (n = 24)	20 mg/2 ml of HA (Hyalgan®)	mixture of O ² O ³ (15 ml) with [O3] of 15 µg/ml, obtained through an ozone generator	2 months from end of treatment	II
Girardi et al. 2015 ¹⁵⁴	RCT	14 patients with internal derangement of temporomandibular joint	2 groups (arthrocentesis + injection): - betamethasone + HA - only betamethasone	0.5 ml of HA	- group I: 0.5 ml of betamethasone; - group II: 1 ml of betamethasone	2 days, 1, 2 weeks, 1, 2, 6 months	II
Lee et al. 2011 ¹⁵⁸	RCT	43 subjects with gonarthrosis	2 groups: - HA+30 mg of ketorolac (3 weeks), followed by HA alone (2 weeks) - only HA for 5 weeks	2.5 ml (1%) of Hyal (940-1020 kDa)	30 mg of ketorolac	1, 3, 5, 16 weeks after beginning of therapy	II
Ozturk et al. 2006 ¹⁵⁵	RCT	40 patients with gonarthrosis	2 groups (3 weekly injections for 3 weeks+3 injections at 6 th month): - HA (n = 24, group A); - HA + triamcinolone at I and IV injection	2 ml of HA (Orthovisc): 15 mg sodium hyaluronate +9 mg sodium chloride/1 ml	1 ml triamcinolone acetamide (Kenacort-A)	1-3, 6, 7, 9, 12 months	II
Palmieri et al. 2013 ¹⁵⁹	RCT	62 patients with bilateral gonarthrosis	3 groups: - 66 mg of HA - 49.5 mg of HA + 5 mg of diclofenac - 49.5 mg of HA + 5 mg of sodium clodronate	- 66 mg/2 ml of HA (Variofill®) - 49.5 mg/1.5 ml of HA (Variofill®)	- 5 mg/0.5 ml of sodium diclofenac; - 5 mg/0.5 ml of sodium clodronate	3 and 6 months	II
Petrella et al. 2015 ¹⁵⁶	RCT	98 subjects with gonarthrosis	3 groups: - HA (Hydros) - HA + 10 mg of triamcinolone acetamide (Hydros TA) - HA (Synvisc-One)	-Hydros -Hydros TA (HA + 10 mg triamcinolone acetamide) -Synvisc-One® (hyalan G-F 20)	10 mg of triamcinolone acetamide	2, 6, 13, 26 weeks	II
Rovetta & Monteforte 1998 ⁸⁹	RCT	30 subjects with adhesive capsulitis	2 groups (injections every 15 days in first month, then monthly for 6 months): - injection of HA + steroids + physiotherapy - injection of steroids + physiotherapy	20 mg of sodium hyaluronate	20 mg of triamcinolone acetamide (both groups)	6 months	II

To be continued

Continue from Table XII.

Saw et al. 2013 ¹⁶¹	RCT	50 patients with chondral lesions of the knee (grade 3-4 ICRS International Cartilage Repair Society)	2 groups (5 weekly injections, started 1 week after arthroscopy + 3 weekly injections after 6 months): - HA only - HA + peripheral blood stem cells (PBSC)	2 ml of HA for each injection	8 ml injection of PBSC	-IKDC: 6, 12, 18, 24 months -MRI: 6, 12, 18 months -biopsy: 18 months	II
Tosun et al. 2015 ¹⁴⁹	RCT	57 patients with clinical diagnosis of lateral epicondylitis	2 groups (1 single injection): - HA + chondroitin sulfate (CS) + prilocaine - triamcinolone + prilocaine	1 ml of laluril (800 mg of HA + 1 g of chondroitin sulphate/50 ml)+0.6 ml of prilocaine HCl (Citanest)	1 ml triamcinolone acetonide (40 mg/ml, Kenacort-A Retard) + 0.6 ml of prilocaine HCl (Citanest)	3 and 6 months after injection	II
Saturveithan et al. 2016 ^v	Retrospective non randomized	64 patients (101 knees) with gonarthrosis	2 groups: - HA + PRP (56 knees) - HA only (45 knees)	4 ml of high-MW HA (1476x106 Da) with a concentration of 22 mg/ml	2.5-3 ml of PRP with an average [PLTs] of 1.4-1.6 million/ μ l	2 and 6 months after injection	II
Briggs et al. 2012 ¹⁵⁷	Clinical trial without control	47 patients (27 females) with diagnosis of gonarthrosis	Cycle of 3 injections: - at I injection brand+HA+Kenalog+lidocaine - at II and III injection only HA	Hylan G-F	- 2 ml of Kenalog-10 (triamcinolone acetonide); - 3 ml of brand (Bupivacaine) - 3 ml of lidocaine	3, 6, 12 weeks and 6 months	III
Conrozier et al. 2016 ¹⁶³	Retrospective clinical trial without control	40 patients with gonarthrosis	1 single injection of HAnox-M-XL (4.4 ml)	HAnox-M-XL 4.4 ml: cross-linked HA (16 mg/ml) + mannitol (35 mg/ml)	35 mg/ml of mannitol	3 and 6 months	III
Henrotin et al. 2012 ¹⁶⁴	Clinical trial without control	30 patients with gonarthrosis	3 weekly injections of sterile solution (2 ml) of HA+chondroitin sulphate (CS)	24 mg of HA	60 mg chondroitin sulfate (Structovial CS)	6 and 12 weeks	III

Association with other drugs/medical devices

Three different studies reported significant clinical benefits with the use of HA in association to oxygen-ozone therapy, mannitol and chondroitin sulfate, respectively, in patients with knee osteoarthritis¹⁶²⁻¹⁶⁴.

Level of recommendation: C.

Keypoints

- The association of HA with other drugs or devices could have advantages in comparison to HA alone.
- Dosage and frequency of association with HA in osteoarticular and myotendinous diseases are not defined.
- Future high quality RCTs are needed in order to improve the knowledge about mechanism of action and efficacy of combined therapies.

KEY WORDS: hyaluronic acid, musculoskeletal, injection, intra-articular, sodium hyaluronate, anesthet-

ic, corticosteroid, NSAIDS, PRP, mesenchymal stem cells, ozon.

Ultrasound guidance for HA injection in musculoskeletal disorders

The advantages of ultrasound (US) imaging (real-time execution, absence of ionizing radiation, low cost and availability of device) are responsible of the large diffusion of US-guidance.

US-guidance in shoulder pathologies

Three studies were selected. Two studies investigated the outcome in patients with adhesive capsulitis^{84,165}, while one study in subacromial pain syndrome (Tab. XIII)¹⁶⁶. All studies reported good clinical results after US-guided injections of HA, at least in the short term.

US-guidance in hand pathologies

Four different studies have reported that US-guided injections of HA appear to be a safe and suitable tool

Table XIII. Selected studies for on US-guided injections.

Author and year	Population	Type of HA	Injection frequency	Follow-up period	Level of evidence
Atchia et al. 2011 ¹⁰⁴	77 patients with unilateral coxarthrosis waiting for surgical total hip replacement	3 ml/60 mg of Durolane	Not specified	1, 4, 8 weeks	II
Battaglia et al. 2013 ¹⁰⁵	100 patients with unilateral coxarthrosis	High molecular weight HA (1500 Kd, Hyalubrix)	3 consecutive injections (every 2 weeks)	1, 3, 6, 12 months	I
Bum Park et al. 2012 ¹⁶⁹	99 subjects with gonarthrosis	2 ml 1% high molecular weight HA (940-1020kDa)	3 weekly intra-articular injections	-	II
Callegari et al. 2011 ¹⁴⁸	30 subjects with stenosing tenosynovitis of finger flexors	1 ml 0.8% HA (Sinovial Mini) +methylprednisolone acetate 40 mg/1 ml (Depo-medrol)	2 injections (10 days between them)	6 weeks, 3, 6, 12 months	II
Kim et al. 2012 ¹⁶⁶	80 patients with subacromial conflict syndrome	2 ml/20 mg of Hyruan plus (average molecular weight 300,000,000 Da)	3 weekly injections (AI group); 1 injection (corticosteroid group)	3, 6, 12 weeks	II
Lee et al. 2009 ¹⁶⁵	43 patients with shoulder adhesive capsulitis	2.5 ml/25 mg of low molecular weight HA	I week: 0.5 ml/20 mg of triamcinolone with 1.5 ml of 2% lidocaine and 3 ml of saline solution; II-VI week: HA	Weekly follow-up	II
Liu et al. 2015 ¹⁴⁷	36 subjects (39 fingers) with clinical diagnosis of trigger finger	1 ml medium molecular weight HA(1000-1200 kDa, Artz)	1 injection	3 weeks, 3 months	II
Monfort et al. 2015 ¹⁶⁸	88 patients with rhizoartrosis	0.5 cm ³ /5 mg of 500-1000kDa HA produced by bacterial fermentation (Suplasyn®)	3 weekly injections	7,14,30,90, 180 days	II
Orlandi et al. 2015 ¹⁶⁷	75 patients with unilateral de Quervain's disease	16 mg/2 ml of low molecular weight HA (0.8%, Sinovial)	2 injections (15 days between them): I injection: steroid; II injection: HA	1, 3, 6 months	I
Park et al. 2013 ⁸⁴	90 patients with shoulder adhesive capsulitis	18 ml of lidocaine 0.5% for capsular distention + 2 ml high MW HA (10 mg/ml)	3 biweekly injections	2 and 6 weeks	II
Qvistgaard et al. 2006 ⁹⁹	101 patients with coxarthrosis	2 ml of HA (Hyalgan®)	3 injections every 14 days	14, 28, 90 days	II

for the treatment of trigger finger, de Quervain's disease and rhizarthrosis^{147,148,167,168}.

US-guidance in hip

US-guided injections of HA have shown good results in three studies on patient with hip osteoarthritis^{99,104,105}. Authors suggested that US could be useful not only as a guide, but also as a biomarker of response to therapy.

US-guidance in knee

One level II study reported that the precision of injection is better for US-guided procedure in comparison

to anatomical landmark injections in suprapatellar bursitis¹⁶⁹.

Level of recommendation for US-guided injection in hip joint: A.

Level of recommendation for US-guided injection in trigger finger: B.

Level of recommendation for US-guided injection in rhizarthrosis, glenohumeral joint and subacromial space: C.

Level of recommendation for US-guided injection in other anatomical sites: D.

Keypoints

- Ultrasound imaging is an effective tool for intra-articular injections guidance in several musculoskeletal disorders, in absence of contraindications and severe side effects.
- While US offers various advantages (cost/benefit ratio, availability, real time acquisition), there is still lack of strong evidence regarding the impact of HA injections with ultrasound guidance in terms of accuracy and benefits in comparison to blinded procedures.

KEY WORDS: *hyaluronic acid guided injection as mesh term.*

Hyaluronic acid and exercise therapy

Four RCTs^{125,170-172} and one review¹⁷⁴ compared the effectiveness of intra-articular injections of HA to a specific rehabilitative protocol in the treatment of patients with knee and ankle osteoarthritis; only one RCT investigated the combination to each treatment in alone (Tab. XIV).

The results lead Authors to conclude that both treatments improve pain and function, although combined treatment seems to guarantee greater efficacy, at least in the short term.

Level of recommendation: B.

Keypoints

- Both HA injections and exercise therapy alone and in combination should improve pain e function in patients affected by OA.
- A single RCT suggested a possible greater efficacy of combined treatment in the short term.
- More studies are needed to strongly support this recommendation.

KEY WORDS: *hyaluronic acid injection, physical exercises, exercise therapy, viscosupplementation, rehabilitation protocol and/or randomized controlled trial, systematic review.*

Hyaluronic acid and physical therapies

In clinical practice the association between HA injection and physical therapies is common. Indeed, the effects of these therapies seem to be complementary and synergistic: in particular, physical therapies show beneficial actions in the acute phase reducing pain and inflammation through thermal, biochemical, mechanical and electrical effects, while HA acts mainly by facilitating and maintaining functional recovery over time.

However, the real effectiveness of physical therapies in musculoskeletal pathologies is controversial and only few scientific studies are aimed at validating the association between them and HA.

Osteoarthritis

Three studies^{6,23,25} show better results with the association of HA and physical therapies compared to physical therapies alone in patients with shoulder and

knee osteoarthritis¹⁷⁴⁻¹⁷⁶ (Tab. XV). One pilot study did not show any significant difference, even both short-term (3 weeks) and long-term (3 months) evaluations, index of severity for osteoarthritis of the knee scores were reduced in all three groups¹⁷⁷.

Adhesive capsulitis

Two studies^{26,27} agree that the addition of HA to conventional treatments (including physical therapies) does not add significant benefits in patient suffering from adhesive capsulitis.

Level of recommendation: C.

Keypoints

- HA and physical therapies are commonly used for the treatment of musculoskeletal pathologies.
- Evidence on the effectiveness of physical therapies in joint and tendon disorders is controversial, mainly because of the lack of high quality RCTs.
- Only few studies demonstrated the effectiveness of association between physical therapies and HA, especially in knee and shoulder osteoarthritis, while there is no evidence on shoulder adhesive capsulitis.

KEY WORDS: *hyaluronic acid injection, physical therapy, lasertherapy, viscosupplementation, rehabilitation protocol, shockwaves, ultrasound, electrotherapy and/or randomized controlled trial, systematic review.*

Hyaluronic acid in post-surgical management

The promising results obtained in the conservative treatment of various musculoskeletal diseases have led many surgeons to propose HA also in post-surgical management, especially after shoulder, knee and ankle arthroscopy (Tab. XVI).

HA after knee arthroscopy

Early viscosupplementation in arthroscopic partial meniscectomy was found to have conflicting results and a possible improvement in short-term pain is not showed in all level I studies¹⁷⁸⁻¹⁸⁰.

Different studies on viscosupplementation after ACL reconstruction evidenced inflammation, swelling and pain reduction only in the immediate post-operative period, without any difference in the long-term^{69,181,182}.

Conversely, three RCTs showed significant pain and clinical scores improvement for HMW HA after knee arthroscopy in knee OA¹⁸³⁻¹⁸⁵.

HA after shoulder arthroscopy

Postoperative capsular stiffness is the main complication after shoulder arthroscopy and may determine prolonged rehabilitation period. HA could be used in post-surgery with the aim of decreasing adhesions and thus facilitating rehabilitation.

However, a recent RCT has not showed significant difference in pain VAS, internal rotation, external rotation and functional scores between two groups at each follow-up period¹⁸⁶.

Table XIV. Selected studies on HA and exercise.

Author and year	Study design	Protocol	Follow-up (weeks)	Outcome measures	Results	Level of evidence
Karatosun et al. 2006 ¹⁷⁰	Randomized	3 injections of Hylan G-F20 (52 patients) Exercise (53 patients)	12,24,48,72	Hospital for Special Surgery (HSS) Knee Score	No differences between groups	II
Karatosun et al. 2008 ¹²⁵	Randomized perspective	3 injections of Hylan G-F20 (19 patients) Exercise (24 patients)	8,12,24,48	American Orthopedic Foot and Ankle Society (AOFAS) score, VAS score	No differences between groups	II
Kawasaki et al. 2009 ¹⁷¹	Randomized perspective	1 injection of ND device (42 patients) Exercise (45 patients)	24	VAS, Japanese Knee Osteoarthritis Measure (JKOM)	No differences between groups	II
Saccomanno et al. 2016 ¹⁷²	Randomized	3 injections of Orthovisc (55 patients) Exercise (55 patients) 3 injections of Orthovisc + Exercise (55 patients)	4,12,24	Western Ontario and McMaster Universities (WOMAC) Index, Active Range of Movement (AROM)	Significant improvement in pain at 1 month in HA + exercise group	I

Table XV. Selected studies on combined HA and physical therapies.

Author and year	Study design	Protocol/pathology	Follow-up (weeks)	Outcome measures	Results	Level of evidence
Di Giacomo & De Gasperis 2015 ¹⁷⁴	Randomized perspective	5 injections of Hyalgan 20 + exercise (31 patients) Physical therapies (30 patients) Glenohumeral osteoarthritis	16, 24	Constant scale	First group (HA+PT) had statistically better results on disability and pain compared to second group (PT)	II
Huang et al., 2005 ¹⁷⁵	Randomized	Injection of ND device + exercises + US (32) Exercises (26) Exercises + US (29) Control (31) Gonarthrosis	8, 1 year	Lequesne scale, VAS, ROM, walking speed, peak of strength	Combined treatment with HA, isokinetic exercises and US gave better results on disability and pain compared to exercises alone or exercises + US at 1 year	II
Bayramoğlu et al., 2003 ¹⁷⁷	Randomized	3 injections of Synvisc® + exercise (12 patients) 3 injections of Orthovisc® + exercise (16 patients) Exercise (9 patients) Gonarthrosis	3,12	Lequesne scale, isokinetic strength	No significant differences in function at 3 weeks and 3 months between treatment with HA+PT (TENS + diathermy) and PT alone	II
Ip & Fu 2015 ¹⁷⁶	Randomized perspective	Exercise + fake irradiation + 5 injections of saline solution (70 patients) Exercise + 5 injections of Hyalgan® +LLLT (70 patients) Gonarthrosis	7 years	WOMAC scale, use of prosthesis	Group B treated with LLLT + low molecular weight HA had greater reduction of pain and minor recourse to prosthetic surgery compared to group A treated with traditional physical therapies like US, ET and diathermy	II

Table XVI. Selected studies on post-surgical management.

Author and year	Study design	Protocol/pathology	Follow-up (weeks)	Outcome measures	Results	Level of evidence
Mathies 2006 ¹⁷⁸	RCT	25 patients: treatment 25 patients: control Arthroscopic meniscectomy	4	VAS, circumference	Less pain and swelling in the first 30 days	I
Thein et al. 2010 ¹⁷⁹	RCT	28 patients: treatment 28 patients: control Arthroscopic meniscectomy	12	VAS, circumference	Less pain, less swelling, equal functional scores	I
Filardo et al. 2016 ¹⁸⁰	RCT	45 patients: treatment 45 patients: control Arthroscopic meniscectomy	24	IKDC, KOOS, VAS, Tegner scores	No difference	I
Heybeli et al. 2008 ¹⁸³	RCT	33 patients: treatment 34 patients: control Gonarthrosis	24	WOMAC, VAS	Better clinical scores at 6 weeks No difference at 24 weeks	I
Westrich et al. 2009 ¹⁸⁴	RCT	23 patients: treatment 23 patients: control Gonarthrosis	24	VAS, functional results	Better results for treatment group	I
Hempfling 2007 ¹⁸⁵	RCT	40 patients: treatment 40 patients: control Gonarthrosis	2 years	VAS, walking ability, functional results	Better results in treatment group	I
Huang et al. 2007 ⁶⁹	RCT	90 patients: treatment 30 patients: control LCA reconstruction	16	Lysholm scale, ROM, walking speed	Better results in treatment group	I
Chau et al. 2012 ¹⁸¹	RCT	16 patients: treatment 16 patients: control LCA reconstruction	12	KOOS, ROM, circumference, use of analgesics	Improvement in pain and swelling at 2 days	I
Di Martino et al. 2016 ¹⁸²	RCT	30 patients: treatment 30 patients: control LCA reconstruction	1 year	ROM, VAS, circumference, SF-36, IKDC, Tegner score	Improvement in ROM and swelling at 30 and 60 days	I
Oh et al. 2011 ¹⁸⁶	RCT	40 patients: treatment 40 patients: control Rotator cuff suture	1 year	VAS, ROM, CONSTANT, ASES	No difference	I
Doral et al. 2012 ¹⁸⁷	RCT	41 patients: treatment 16 patients: control Chondral lesions of astragalus	2 years	Freiburg, AOFAS score	Better results for treatment group	I
Görmeli et al. 2015 ¹⁸⁸	RCT	13 patients: PRP 14 patients: HA 13 patients: control Chondral lesions of astragalus	60	AOFAS score, VAS	Better results in PRP and HA groups compared to controls	I

HA after foot and ankle surgery

Two different level I RCTs showed that HA in addition to microfractures could offer better clinical results in osteochondral lesions of the talus^{187,188}.

Level of recommendation: A after knee arthroscopy in knee OA patients.

Level of recommendation: D after knee arthroscopic meniscectomy and ACL surgery.

Level of recommendation: A in post-surgical pain management.

Level of recommendation: C after shoulder arthroscopy and foot and ankle surgery.

Keypoints

- HA may determine improve in pain in the early post-operative period after knee arthroscopy.
- HA does not appear to offer any long-term clinical benefit after arthroscopic meniscectomy and LCA surgery.
- Further studies are needed to recommend the use of HA after shoulder and ankle surgery.

KEY WORDS: *hyaluronic acid, viscosupplementation, sodium hyaluronate, knee arthroscopy, knee surgery, shoulder arthroscopy, shoulder surgery, ankle arthroscopy, ankle surgery, ligaments and tendons, tendon surgery.*

Contraindications and adverse effects

Fifty-seven studies (40 RCTs and 17 systematic reviews) were selected^{65,78,98,99,101,102,104,107,108, 114,136,139, 140,148,156,158,159,189-227}.

Absolute contraindications are represented by hypersensitivity to products, suspect or presence of infections at injection skin site or selected joint, joint inflammatory states.

As intra-articular injection represents an invasive procedure, should be carefully considered in patients suffering from hematological disorders.

Hepatic pathologies and venous and/or lymphatic stasis could affect HA metabolism.

Considering the lack of scientific evidence regarding HA safety in pregnancy, breast-feeding and in the pediatric population, viscosupplementation is contraindicated in these conditions (Tab. XVII).

Adverse effects are of minor entity, as usually not limit daily life activities and disappear in a few hours or days (Tab. XVIII).

Minor adverse effects include local superficial or articular pain and/or swelling, myalgia, upper respiratory tract disorders, headache, paresthesia, lipothymia, gastrointestinal minor disorders, general fatigue, skin rash, local pruritus, urticaria, allergic manifestations, phlebitis and other minor events.

Only few studies reported more serious adverse events

that however concerned a negligible percentage of included subjects and were considered improbable and unrelated to the treatment.

Level of recommendation: A for safety and tolerability of HA products.

Keypoints

- HA injections are well tolerated.
- Adverse effects due to HA injections are not frequent, minor and transient; serious adverse events recorded were not related to treatment.

KEY WORDS: *hyaluronic acid injection, side effects, contraindication.*

Authors contributions

I.S.Mu.L.T. - ITALIAN SOCIETY OF MUSCLES LIGAMENTS & TENDONS. Italian version of the Guidelines: "Linee Guida I.S.Mu.L.T. Trattamento infiltrativo con acido ialuronico nelle patologie dell'apparato muscolo-scheletrico" IBSA Farmaceutici Italia, Edra Editore, 2017.

Coordinators

Filippo Vittadini, Antonio Frizziero, Francesco Oliva.

Group of the experts

Giovanni Abatangelo, Asmaa Mahmoud, Daniela Buonocore, Roberto Buda, Maurizia Dossena, Luigi Frizziero, Stefano Galletti, Alessio Giai Via, Giovanni Merolla, Alberto Migliore, Simone Nicoletti, Antonello Padolino, Marco Terreni, Alessandro Valent, Manuela Verri, Mario Vetranò.

Overseeing group

Anna C Berardi, Francesco Ceccarelli, Cosimo Costantino, Cesare Faldini, Calogero Foti, Nicola Maffulli, Giuseppe Porcellini, Maria Chiara Vulpiani.

Group of preparation and evaluation of the literature

Serenella Bacciu, Michela Bossa, Filippo Calderazzi, Antonio Carolla, Paolo Finotti, Giuseppe Gasparre, Simone Natali, Leonardo Pellicciari, Eleonora Piccirilli, Eleonora Pintus, Davide Romiti, Antonella Vertuccio.

Table XVII. Contraindications reported on leaflets of each HA formulation considered.

Trade name	Hyper-sensitivity to HA	Skin infections	Joint infections	Joint phlogosis	Pregnancy /lactation	Lymphatic/venous stasis	Liver pathologies	Pediatric age	Blood disorders
Arthrhum	0	0	0	0	0	0	0	0	0
Arthrhum 2.5%	0	0	0	0	0	0	0	0	0
Artrosulfur HA	0	1	1	1	0	0	0	0	0
Artz/Supartz	1	0	0	0	1	0	1	1	0
Condrovisc	0	1	1	1	1	0	0	0	0
Coxarthrum	1	0	1	1	0	0	0	0	0
Durolane (AF)	0	1	0	0	1	0	0	1	0
Euflexxa	1	1	1	0	1	0	0	0	0
Femathron (AF)	1	1	1	0	0	0	0	0	0
Go-on	1	0	0	1	0	0	0	0	0
Go-on Mini	1	0	0	1	0	0	0	0	0
Go-on matrix	1	1	1	1	0	1	0	0	0
Hyalart	1	0	0	0	0	0	1	0	0
Hyalgan	1	0	0	0	0	0	1	0	0
Hyalubrix	1	1	0	0	0	0	0	0	0
Hyalubrix 60*	1	1	0	0	0	0	0	0	0
Hymovis	1	1	0	0	0	0	0	0	0
Inartral	1	1	0	0	0	0	0	0	0
Intrageel (AF)	0	1	1	1	0	0	0	0	0
Jointex (AF)	0	1	1	1	0	0	0	0	0
Jonexa	1	1	1	0	0	1	0	0	0
Kartilage (AF)	1	0	0	1	0	0	0	0	0
MonoVisc	1	1	0	0	0	0	0	0	1
OrthoVisc (AF)	1	0	0	0	1	0	0	0	0
Ostenil (AF)	1	0	0	0	0	0	0	0	0
Proial	1	1	1	0	0	0	0	0	0
Promovia	0	1	0	0	0	0	0	0	0
RenehaVis	1	0	0	0	0	0	0	0	0
Rhizarthrum	1	0	1	1	0	0	0	0	0
Sinovial (AF)	0	1	1	1	0	0	0	0	0
SportVis	1	1	0	0	0	0	0	0	0
Structovial	1	0	1	0	0	0	0	0	0
Synocrom (AF)	1	0	1	0	0	0	0	0	0
Synolis V-A	1	1	1	0	1	0	0	1	0
Synvisc (AF)	0	1	1	1	0	1	0	0	0
Yaral (AF)	0	1	1	1	0	0	0	0	0
Viscoplus (AF)	0	0	0	0	0	0	0	0	0

Notes: * also Hyalone; AF: all formulations of the same brand.

Table XVIII. Adverse events reported in selected studies after HA injection.

Author and year	Study design	Population	Treatments	Type of HA	Adverse events	Level of evidence
Abate et al. 2008 ¹⁸⁹	Systematic review	17 clinical trials (coxarthrosis)		No difference between HA formulations (data not shown)	- pain at injection site - heaviness at injection site	I
Altman et al. 1998 ¹⁹²	RCT multicenter	495 patients with idiopathic gonarthrosis	3 treatment groups: - HA - placebo - naproxen	2 ml/20 mg Hyalgan	- pain at injection site - gastrointestinal disorders - swelling/effusion - death (pre-existing cardiovascular disorders)	I
Altman et al. 2009 ¹⁹³	RCT	588 subjects with gonarthrosis	2 groups: - Phosphate Buffered Saline (PBS) - BioHA	20 mg/2 ml of EUFLEXXA® (1% bio-engineered sodium hyaluronate)	- pain at injection site - arthralgia - pneumonia - TIA	I
Altman et al. 2011 ¹⁹⁴	RCT	433 subjects with gonarthrosis	2 groups: - PBS - BioHA	20 mg/2 ml of EUFLEXXA® (1% bio-engineered sodium hyaluronate)	- pain at injection site - arthralgia - rhinopharyngitis - other upper airways infections - soft tissue edema adjacent to injection site - joint swelling - peripheral edema	I
Arden et al. 2014 ¹⁹⁵	RCT	208 patients with gonarthrosis	2 groups: - 3 ml of NASHA (Not Animal Stabilized HA) - 3 ml of saline solution buffered at pH 7	60 mg/3 ml of Durolane (NASHA with unique cross-linked molecular structure)	pain at injection site	I
Arrich et al. 2005 ¹⁹⁶	Systematic review	22 studies (gonarthrosis)		Hyalgan 500-730 kDa Orthovisc 1000-2900kDa HA nms 600-1200 kDa Artz 600-1200 kDa Artzal ~ 1000 kDa Synvisc ~ 7000 kDa Suplasyn 500-730 kDa BioHy 2400-3600 kDa	pain at injection site	I
Atchia et al. 2011 ¹⁰⁴	RCT	77 patients with unilateral coxarthrosis waiting for total hip arthroplasty	4 groups: - standard treatment (without infiltrations) - saline solution - NASHA - methylpre-dnisolone acetate (Depomedrol)	3 ml/60 mg of Durolane	post-arthroplasty infection	I
Bannuru et al. 2014 ¹⁹⁷	Systematic review	5 studies (gonarthrosis)		Synvisc, Hyalgan, Suplasyn, Suvenyl	- pain at injection site - TIA - myocardial infarction	I
Bellamy et al. 2005 ¹⁹⁸	Cochrane review	63 trials (gonarthrosis)		Hyaluronate and hylan derivates (Adant, ArthrumH, Artz: Artzal, Supartz), BioHy (Arthrease), Durolane, Fermathron, Go-On, Hyalgan, Hylan G-F 20 (Synvisc Hylan G-F 20), NRD-101, Orthovisc, Ostenil, Replasyn, SLM-10, Suplasyn, Synject and Zeel compositum	- pain at injection site - joint swelling - gastrointestinal disorders - hemarthrosis - phlebitis - skin rash - pruritus	I

Continue from **Table XVIII.**

Blaine et al. 2006 ⁶⁵	RCT	660 subjects with shoulder pain	3 groups: - 5 infiltrations of HA - 3 infiltrations of HA + 2 of saline solution - 5 infiltrations of saline solution	2 ml Hyalgan (10 mg/ml)	- pain at injection site - arthralgia - rhinopharyngitis - headache - vertebral pain	I
Brandt et al. 2001 ²⁰⁰	RCT	226 patients with gonarthrosis	2 groups: - HA - saline solution	2 ml (15 mg/ml) of ORTHOVISC, high MW hyaluronic acid, extract from cock's crests	- pain at injection site - arthralgia - local inflammation - bruising - generalized fatigue - gastrointestinal diseases	I
Brzusek et al. 2008 ²⁰¹	Systematic review	16 studies (gonarthrosis)		Euflexxa, Orthovisc, Hyalgan, Supartz, Synvisc	- pain at injection site - joint swelling	I
Callegari et al. 2011 ¹⁴⁸	RCT	30 subjects with stenosing tenosynovitis of finger flexor	2 groups: - group A: corticosteroids + HA - group B: open surgery	1 ml 0.8% HA (Sinovial Mini) + methyl prednisolone acetate 40 mg/1 ml (Depo-medrol)	No adverse events	I
Chang et al. 2013 ²¹⁶	Systematic review	9 studies (ankle osteoarthritis)		Not specified	- post-injection pain - increase in volume of inguinal lymph nodes - localized pruritus - dissecans osteochondritis (4 months after treatment)	I
Chevalier et al. 2010 ²⁰²	RCT	253 patients with gonarthrosis	2 groups: - arthrocentesis + infiltration of HA - arthrocentesis + injection saline solution	6 ml of Hylan G-F 20 (Synvisc-One)	- pain at injection site - joint stiffness - intraarticular effusion - joint swelling	I
Lee et al. 2011 ¹⁵⁸	RCT	43 subjects with gonarthrosis	2 groups: - HA + 30 mg ketorolac (3 weeks), followed by HA alone (2 weeks) - HA alone for 5 weeks	2.5 ml (1%) of Hyal (MW: 940-1020 kDa)	- pain at injection site (HA+ketorolac group)	I
Day et al. 2004 ¹⁰⁸	RCT multicentric study	223 patients with gonarthrosis	2 groups: - HA in saline solution - only saline solution	25 mg of ARTZ (extract from cock's crest, MW 6.2×105-11.7×105 Da)	pain at injection site	I
Diracoglu et al. 2009 ²²²	RCT	63 patients with bilateral gonarthrosis	2 groups: - HA - placebo	Hylan G-F 20 (Synvisc)	No adverse events	I

To be continued

Continue from Table XVIII.

Espal-largues et al. 2003 ²⁰³	Systematic review	14 studies (gonarthrosis)		Hylan G-F 20	- pain at injection site - muscle cramps - hemorrhoids - impatience	I
Fernández López et al. 2006 ²²⁴	Systematic review	8 studies (coxarthrosis)		Not specified	No adverse events	I
Filardo et al. 2012 ²⁰⁴	RCT	109 patients with knee chondropathy or gonarthrosis	2 groups: - PRP - HA	Hyalubrix (HA with MW > 1500 kDa)	pain at injection site	I
Fuchs et al. 2005 ²²³	RCT	60 patients with chronic non radicular lumbar pain	2 groups: - HA - triamcinolone acetonide	10 mg of Ostenil® mini, highly purified HA, from bacterial fermentation, in 1 ml of saline solution	No adverse events	I
Fuchs et al. 2006 ¹³⁶	RCT	56 patients with rhizarthrosis	2 groups: - HA - triamcinolone acetonide	10 mg/1 ml of Ostenil® mini (1,2 MDa)	- lipotimia - pain at index finger - sciatica - pulmonary carcinoma	I
Oh et al. 2011 ¹⁸⁶	RCT	80 subjects submitted to rotator cuff surgical repair	2 groups: Al/carboxymethylated cellulose no treatment	5 g of HA / carboxymethylated cellulose (CMC): Guardix-Sol®	No adverse events	I
Ishijima et al. 2014 ²¹⁸	RCT	200 patients with gonarthrosis	2 groups: - NSAIDs - HA	25 mg of high MW HA (2700 kDa), Chugai Pharmaceutical Co.	joint stiffness	I
Jørgensen et al. 2010 ²⁰⁵	RCT	337 patients with gonarthrosis	2 groups: - HA - saline solution	2 ml of sodium hyaluronate (Hyalgan, 10 mg / ml)	pain at injection site	I
Jüni et al. 2007 ²¹⁹	RCT	660 patients with gonarthrosis	3 groups: - High MW crosslinked HA derived from cock's crest (Synvisc) - Medium-MW non-crosslinked HA derived from cock's crest (Orthovisc) - Low MW non cross-linked HA obtained through bacterial fermentation (Ostenil)	2 ml of Synvisc, Orthovisc and Ostenil	- joint effusion - redness at injection site - septic arthritis - anaphylactic shock	I
Lee et al. 2006 ²⁰⁶	RCT	146 subjects with gonarthrosis	2 groups: - High MW HA - Low MW HA	Hyruan Plus (high MW 3000 kD), Hyal (medium MW 750 kD)	- pain at injection site - localized pruritus - urticaria - myalgia - paresthesias	I
Leighton et al. 2014 ²⁰⁷	RCT	442 subjects with gonarthrosis	2 groups: NASHA Methylpredni-solone acetate (MPA)	60 mg/3 ml of Durolane	- pain at injection site - arthralgia - joint stiffness - joint swelling	I

To be continued

Continue from **Table XVIII.**

Lundsgaard et al. 2008 ²²⁵	RCT	251 subjects with gonarthrosis	3 groups: - 2 ml of HA - 20 ml saline solution - 2 ml saline solution	2 ml of Hyalgan (10.3 mg/ml)	No adverse events	I
Maheu et al. 2011 ²⁰⁸	RCT	276 patients with gonarthrosis	2 groups: - 20 mg of medium MW HA (F60027) - 16 mg of high MW HA (Hylan G-F20)	20 mg of F60027 (Structorial) 16 mg of Hylan G-F20 (Synvisc)	pain at injection site	I
Medina et al. 2006 ²²⁰	Systematic review	7 studies (gonarthrosis)	-	Artzal, Synvisc, Hyalgan, Durolane, Suplasyn, NRD101	allergic manifestations: - sweating - pallor - feeling of thoracic or epigastric oppression - cyanotic skin - hypotension	I
Migliore et al. 2009 ¹⁰²	RCT	42 subjects with coxarthrosis	2 groups: - 4 ml HA derived from bacterial fermentation - 4 ml mepivacaine 2%	4 ml of Hyalubrix (60 mg)	pain at injection site	I
Munteanu et al. 2011 ¹⁴⁰	RCT	151 patients with osteoarthritis of first metatarsophalangeal joint	Participants randomly allocated to receive up to 1 ml intraarticular injection of both Hylan G-F20 or placebo	Hylan G-F 20 (Synvisc)	cellulitis at injection site	I
Navarro-Sarabia et al. 2011 ¹¹⁴	RCT	306 subjects with gonarthrosis	2 groups: - HA - saline solution	2.5 ml (1%) of medium MW (900000 Da) sodium hyaluronate, obtained from fermentation of <i>Streptococcus zoopidemicus</i> (Adant)	allergic reaction not specified	I
Neustadt et al. 2005 ²⁰⁹	RCT multicenter	327 patients with gonarthrosis	3 groups: - 4 injections of high MW HA (O4) - 3 HA and 1 arthrocentesis (O3A1) - 4 arthrocentesis (A4)	2 ml / 30 mg of highly purified high MW HA (Orthovisc, 1-2,9 MDa)	- pain at injection site - arthralgia - hematoma/ecchymosis at injection site - rhinopharyngitis - headache - vertebral pain - heart attack -gastrointestinal bleeding	I
Oliveras-Moreno et al. 2008 ²²⁶	RCT	41 subjects with pain at temporomandibular joint (Wilkes stage II)	2 groups: - HA - methocarbamol + paracetamol	1 ml of sodium hyaluronate 1% (Ostenil mini)	No adverse events	I
Özgen et al. 2012 ⁷⁸	RCT	24 subjects with tendinitis of supraspinatus	2 groups: - HA - physical means	2 ml/16 mg of G-F 20 with a MW of 6x10 ⁶	No adverse events	I
Palmieri et al. 2013 ¹⁵⁹	RCT	62 patients with bilateral gonarthrosis	3 groups: - 66 mg of HA - 49.5 mg of HA + 5mg of diclofenac	66 mg/2 ml of HA (Variofill®)	No adverse events	I

To be continued

Continue from Table XVIII.

			sodium - 49.5 mg of HA + 5mg of sodium clodronate			
Petrella et al. 2015 ¹⁵⁶	RCT multicenter	98 subjects with gonarthrosis	3 groups: - HA (Hydros) - HA + triamcinolone acetronide 10 mg (Hydros TA) - HA (Synvisc-One)	- Hydros (hydrogel with HA suspended in HA solution) - Hydros TA (HA+10 mg triamcinolone acetronide) - Synvisc-One® (hylan G-F 20)	- arthralgia - joint swelling - joint stiffness - vertebral pain - colitis - bronchopneumonia - meniscal lesion	I
Qvistgaard et al. 2006 ⁹⁹	RCT	101 patients with coxarthrosis	3 groups: - 1ml/40 mg methylpredni-solone + 2 fake injections - 3 injections HA (2 ml)- 3 injections of saline solution (2 ml)	2 ml of HA (Hyalgan®)	pain at injection site	I
Reichen- bach et al. 2007 ²¹¹	Systematic review	13 studies (gonarthrosis)		Artzal, Orthovisc, Hyalgan, Ostenil, Bio-Hy	- pain at injection site - joint swelling	I
Richette et al. 2009 ¹⁰¹	RCT	122 patients with symptomatic coxarthrosis	2 groups: - HA - saline solution	2.5 ml of HA (Adant) obtained from Streptococcus fermentation with average MW 900000 Da	- pain at injection site - hematoma at injection site - pruritus	I
Saito et al. 2009 ²¹²	Systematic review	5 studies (knee rheumatoid arthritis)		Not specified	pain at injection site	I
Saito et al. 2010 ¹⁹¹	Systematic review	19 studies (chronic shoulder pain)		NRD 101, Artz (900 kD), SLM-10 (1900 kD), Hyalart, Subenyl (1900 kD), Orthovisc (1000- 2900 kD), Hyalgan (500- 730 kD)	- pain at injection site - joint swelling	I
Shi et al. 2003 ¹⁹⁰	Cochrane review	11 studies (temporo- mandibular joint disorders)			- discomfort at injection site - joint swelling	I
Stahl et al. 2005 ¹³⁹	RCT	52 patients with grade II rhizoartrosis	2 groups: - methyl- prednisolone acetate - HA	15 mg of sodium hyaluronate (Ortho-Visc)	No adverse events	I
Strand et al. 2012 ²²⁷	RCT	379 patients with gonarthrosis	2 groups: - HA - PBS	30 mg/3 ml crosslinked HA (Gel-200)	No adverse events	I
Tang 2012 ²²¹	RCT	162 patients with knee Kashin-Beck disease	2 groups: - Intra-articular HA - meloxicam per os	25 mg of HA (10 g/ml, > 800 kDa)	local reactions at injection site	I
Tikiz et al. 2005 ⁹⁸	RCT	43 patients with coxarthrosis	2 groups: - Low MW HA - High MW HA	- Low MW HA (Ostenil, 1,2-1,4x106 Da; 1%) - High MW HA(hylan G-F 20, Synvisc, 7x106Da)	- pain at injection site - joint swelling	I

To be continued

Continue from Table XVIII.

Waddell et al. 2007 ¹⁰⁷	Systematic review	(gonarthrosis)		Synvisc (hylan G-F 20), Hyalgan (sodium hyaluronate), Supartz (sodium hyaluronate), Orthovisc (high MW HA) and Euflexxa (1% sodium hyaluronate)	- pain at injection site - joint swelling	I
Wang et al. 2004 ²¹³	Systematic review	20 studies (gonarthrosis)		Cross-linked HA (Synvisc), non-cross-linked HA (Hyalgan, Orthovisc, Artz) and bio-engineered HA	- pain at injection site - joint swelling - vasculitis - hypersensitivity reactions	I
Wobig et al. 1998 ²¹⁷	RCT	110 patients with gonarthrosis	2 groups: - HA - saline solution	2 ml of hylan G-F 20	- muscle cramps - hemorrhoids - impatience	I
Wobig et al. 1999 ²¹⁴	RCT	70 patients with gonarthrosis	2 groups: - High MW HA - Low MW HA	- High MW HA (hylan G-F 20, 0.8%) - Low MW HA (1%)	- pain at injection site - joint swelling - intraarticular effusion	I
Yu et al. 2014 ²¹⁵	Systematic review	7 studies (gonarthrosis in KBD)	-	-	- pain at injection site - joint swelling - intraarticular effusion - bleeding at injection site	I

References

- Balazs EA, Laurent TC, Jeanloz RW. Nomenclature of hyaluronic acid. *Biochem J.* 1986;235:903.
- Turley EA, Noble PW, Bourguignon LY. Signaling properties of hyaluronan receptors. *J Bio Chem.* 2002;277:4589-4592.
- Toole BP, Wight TN, Tammi MI. Hyaluronan-cell interactions in cancer and vascular disease. *J Biol Chem.* 2002;277:4593-4596.
- Hascall VC, Majors AK, de la Motte CA, Evanko SP, Wang A, Drazba JA, et al. Intracellular hyaluronan: a new frontier for inflammation? *Biochim Biophys Acta.* 2004;1673:3-12.
- Kogan G, Soltes L, Stern R, Gemeiner P. Hyaluronic acid: a natural biopolymer with a broad range of biomedical and industrial applications. *Biotechnol Lett.* 2007;29:17-25.
- Darke A, Finer EG, Moorhouse R, Rees DA. Studies of hyaluronate solutions by nuclear magnetic relaxation measurements. Detection of covalently defined, stiff segments within the flexible chains. *J Mol Biol.* 1975;99:477-486.
- Ribitsch G, Schurz J, Ribitsch V. Investigation of the solution structure of hyaluronic acid by light-scattering, SAXS and viscosity measurements. *Colloid Polym Sci.* 1980;258:1322-1334.
- Faga A, Nicoletti G, Brenta F, Scevola S, Abatangelo G, Brun P. Hyaluronic acid three-dimensional scaffold for surgical revision of retracting scars: a human experimental study. *Int Wound J.* 2013;10:329-335.
- Nicoletti G, Brenta F, Bleva M, Pellegatta T, Malovini A, Faga A, Perugini P. Long-term in vivo assessment of bioengineered skin substitutes: a clinical study. *J Tissue Eng Regen Med.* 2015;9:460-468.
- Necas J, Bartosikova L, Brauner P, Kolar J. Hyaluronic acid (hyaluronan): a review. *Veterinari Medicina* 2008; 53: 397-411.
- Chen WYJ and Abatangelo G. Functions of hyaluronan in wound repair. *Wound Repair Regen.* 1999;7:79-89.
- Entwistle J, Hall CL, Turley EA. Receptors: regulators of signalling to the cytoskeleton. *J Cell Biochem.* 1996;61:569-577.
- Stephens MB, Beutler AI, O'Connor FG. Musculoskeletal injections: a review of the evidence. *Am Fam Physician.* 2008 Oct;78(8):971-976.
- Sala DR. Manuale di infiltrazione. Edizione Italiana a cura di D'Avola G, Morelli A, Zoppi U. Torino, Italy: Ed. Minerva Medica. 1997:96.
- Douglas L and PCRS Members. The Primary Care Rheumatology Society Joint and Soft Tissue Injection Guidelines. The Primary Care Rheumatology Society. 2014 Jan:12.
- Hawker GA, Grigoriadis E, Fam AG. Principles of joint and periarticular aspirations and injections. In: Lawry GV, Kreder HJ, Hawker GA, Jerome D, editors. *Fam's musculoskeletal examination and joint injection techniques*, 2nd edition. Philadelphia, PA: Mosby Elsevier. 2010:127-130.
- Pfenninger JL. Injections of joints and soft tissue: Part I. General guidelines. *Am Fam Physician.* 1991 Oct;44(4):1196-1202.
- Falco FJE, Onyewu CO, Irwin Jr FL, Kim DW, Zhu J. Peripheral Joint, Soft Tissue and Spinal Injection Techniques. In: Braddom RL, editor. *Physical Medicine and Rehabilitation*. 3rd edition. Elsevier Health Science. 2006:541-562.
- Courtney P, Doherty M. Joint aspiration and injection. *Best Pract Res Clin Rheumatol.* 2005;19(3):345-369.
- Hamburger MI, Lakhnani S, Moor PA, Oster D. Intra-articular hyaluronans: a review of product-specific safety profiles. *Semin Arthritis Rheum.* 2003 Apr;32(5):296-309.
- Hirota W. Intra-articular injection of hyaluronic acid reduces total amounts of leukotriene C4, 6-keto-prostaglandin F1 α , prostaglandin F2 α and IL-1 β in synovial fluid of patients with internal derangement in disorders of the temporomandibular joint. *Br J Oral Maxillofac Surg.* 1998;36:35-38.
- Campo GM, Avenosa A, Nastasi G, Prestipino V, Vaccaro M, D'Ascola A, et al. Hyaluronan reduces inflammation in experimental arthritis by modulating TLR-2 and TLR-4 cartilage expression. *Biochim Biophys Acta.* 2011 Sep;1812(9):1170-1181.
- Kaneko S, Satoh T. Interleukin-6 and interleukin-8 levels in serum and synovial fluid of patients with osteoarthritis. *Cytokines Cell Mol Ther.* 2000;6:71-79.
- Goto M, Hanyu T. Intra-articular injection of hyaluronate (SI-

- 6601D) improves joint pain and synovial fluid prostaglandin E2 levels in rheumatoid arthritis: a multicenter clinical trial. *Clin Exp Rheumatol*. 2001;19:377-383.
25. Yasui T, Akatsuka M, Tobetto K, Hayaishi M, Ando T. The effect of hyaluronan on interleukin-1 alpha-induced prostaglandin E2 production in human osteoarthritic synovial cells. *Agents Actions Sep*. 1992;37(1e2):155e6.
 26. Takahashi K, Goomer RS. The effect of hyaluronan on matrix metalloproteinase-3 (MMP-3), interleukin-1 β (IL-1 β), and tissue inhibitor of metalloproteinase-1 (TIMP-1) gene expression during the development of osteoarthritis. *Osteoarthritis Cartilage*. 1999;7:182-190.
 27. Punzi L, Schiavon F, Cavasin F, Ramonda R, Gambari PF, Todesco S. The influence of intra-articular hyaluronic acid on PGE-2 and cAMP of synovial fluid. *Clin Exp Rheumatol*. 1989;7:247-250.
 28. Punzi L. The complexity of the mechanisms of action of hyaluronan in joint diseases. *Clin Exp Rheumatol*. 2001;19:242-246.
 29. Oliviero F, Scanu A, Ramonda R, Frallonardo P, Sfriso P, Daye JM, Punzi L. IL-1 β and IL-8 are scavenged by the hexadecylamide derivative of hyaluronic acid: a new mechanism. *J Biomed Mater Res A*. 2015 Sep;103(9):2823-2829.
 30. Schiraldi C, Stellavato A, de Novellis F, La Gatta A, De Rosa M. Hyaluronan viscosupplementation: state of the art and insight into the novel cooperative hybrid complexes based on high and low molecular weight HA of potential interest in osteoarthritis treatment. *Clin Cases Miner Bone Metab*. 2016 Jan-Apr;13(1):36-37.
 31. Kang Y, Eger W, Koepf H, Williams JM, Kuettner KE, Homandberg GA. Hyaluronan suppresses fibronectin fragment-mediated damage to human cartilage ex-plant cultures by enhancing proteoglycan synthesis. *J Orthop Res*. Nov 1999;17(6):858e869.
 32. Fukuda K, Dan H, Takayama M, Kumano F, Saitoh M, Tanaka S. Hyaluronic acid increases proteoglycan synthesis in bovine articular cartilage in the presence of interleukin-1. *J Pharmacol Exp Ther Jun*. 1996;277(3):1672e1675.
 33. Greenberg DD, Stoker A, Kane S, Cockrell M, Cook JL. Biochemical effects of two different hyaluronic acid products in a co-culture model of osteoarthritis. *Osteoarthritis Cartilage*. 2006 Aug;14(8):814-822.
 34. Oliveira MZ, Albano MB, Namba MM, da Cunha LA, de Lima Gonçalves RR, Trindade ES, et al. Effect of hyaluronic acids as chondroprotective in experimental model of osteoarthritis. *Rev Bras Ortop*. 2014 Feb 12;49(1):62-68.
 35. Yatabe T, Mochizuki S, Takizawa M, Chijiwa M, Okada A, Kimura T, et al. Hyaluronan inhibits expression of ADAMTS4 (aggrecanase-1) in human osteoarthritic chondrocytes. *Ann Rheum Dis*. 2009;68:1051-1058.
 36. Koga H. Effects of hyaluronic acid on arthritic articular cartilage. *Connect Tissue Res*. 2012;53(1):48-93.
 37. Li J, Gorski DJ, Anemaet W, Velasco J, Takeuchi J, Sandy JD, et al. Hyaluronan injection in murine osteoarthritis prevents TGF β 1-induced synovial neovascularization and fibrosis and maintains articular cartilage integrity by a CD44-dependent mechanism. *Arthritis Res Ther*. 2012;14(3):R151.
 38. Mihara M, Hashizume M. The effect of high molecular hyaluronic acid on the induction of matrix degradation enzymes by IL-6, IL-1 β and TNF- α . *Osteoarthr Cartil*. 2012;20:S134-135.
 39. Hashimoto S, Setareh M, Ochs RL, Lotz M. Fas/Fas ligand expression and induction of apoptosis in chondrocytes. *Arthritis Rheum*. 1997;40:1749-1755.
 40. Hashimoto S, Ochs RL, Komiya S, Lotz M. Linkage of chondrocyte apoptosis and cartilage degradation in human osteoarthritis. *Arthritis Rheum*. 1998;41:1632-1638.
 41. Grishko V, Xu M, Ho R, Mates A, Watson S, Kim JT, et al. Effects of hyaluronic acid on mitochondrial function and mitochondria-driven apoptosis following oxidative stress in human chondrocytes. *J Biol Chem*. 2009 Apr 3;284(14):9132-9139.
 42. Peng H, Zhou JL, Liu SQ, Hu QJ, Ming JH, Qiu B. Hyaluronic acid inhibits nitric oxide-induced apoptosis and dedifferentiation of articular chondrocytes in vitro. *Inflamm Res*. 2010 Jul;59(7):519-530.
 43. Kobayashi K. The suppressive effect of hyaluronan on nitric oxide production and cell apoptosis in the central region of meniscus following partial meniscectomy. *Iowa Orthop J*. 2002;22:39-41.
 44. Takahashi K, Hashimoto S, Kubo T, Hirasawa Y, Lotz M, Amiel D. Hyaluronan suppressed nitric oxide production in the meniscus and synovium of rabbit osteoarthritis model. *J Orthop Res*. 2001;19(3):500-503.
 45. Balazs EA. Analgesic effects of elastoviscous hyaluronan solutions and the treatment of osteoarthritic pain. *Cell Tissue Organs*. 2003;174:49-72.
 46. Natura G, Bär KJ, Eitner A, Boettger MK, Richter F, Hensellek S, et al. Neuronal prostaglandin E2 receptor subtype EP3 mediates antinociception during inflammation. *Proc Natl Acad Sci USA*. 2013 Aug 13;110(33):13648-13653.
 47. Caires R, Luis E, Taberner FJ, Fernandez-Ballester G, Ferrer-Montiel A, Balazs EA, et al. Hyaluronan modulates TRPV1 channel opening, reducing peripheral nociceptor activity and pain. *Nat Commun*. 2015 Aug 27;6:8095.
 48. Gomis A, Pawlak M, Balazs EA, Schmidt RF, Belmonte C. Effects of different molecular weight elastoviscous hyaluronan solutions on articular nociceptors afferents. *Arthritis Rheum*. 2004;50:314-326.
 49. Gomis A, Miralles A, Schmidt RF, Belmonte C. Nociceptive nerve activity in an experimental model of knee joint osteoarthritis of the Guinea pig: effects of intra-articular hyaluronan application. *Pain*. 2007;130:126-136.
 50. Gomis A, Miralles A, Schmidt RF, Belmonte C. Intra-articular injections of hyaluronan solutions of different elastoviscosity reduce nociceptive nerve activity in a model of osteoarthritic knee joint of the Guinea pig. *Osteoarthritis Cartilage*. 2008;17:798-804.
 51. Grubb BD. Models of inflammation used to study the properties of articular nociceptors. Pain in osteoarthritis. Edited by Felson DT and Schaible HG; Wiley-Blackwell. 2009.
 52. Boettger MK, Kümmel D, Harrison A, Schaible HG. Evaluation of long-term antinociceptive properties of stabilized hyaluronic acid preparation (NASHA) in an animal model of repetitive joint pain. *Arthritis Res Ther*. 2011;13:R110.
 53. Zavan B, Ferroni L, Giorgi C, Calò G, Brun P, Cortivo R, et al. Hyaluronic acid induces activation of the k-opioid receptor. *Plos One* 2013;8:e55510. Epub. 2013 Jan 28.
 54. Hiraoka N, Takahashi KA, Arai Y, Sakao K, Mazda O, Kishida T, et al. Intra-articular injection of hyaluronan restores the aberrant expression of matrix metalloproteinase-13 in osteoarthritic subchondral bone. *J Orthop Res*. 2011 Mar;29(3):354-360.
 55. Mladenovic Z, Saurel AS, Berenbaum F, Jacques C. Potential role of hyaluronic acid on bone in osteoarthritis: matrix metalloproteinases, aggrecanases, and RANKL expression are partially prevented by hyaluronic acid in interleukin 1-stimulated osteoblasts. *J Rheumatol*. 2014 May;41(5):945-954.
 56. Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. *Cytokine Growth Factor Rev*. 2004 Dec;15(6):457-475.
 57. Ghosh P, Smith MM. The synthesis of hyaluronic acid by human synovial fibroblasts is influenced by the nature of the hyaluronan in the extracellular environment. *Reumatol Int*. 1987;7(3):113-122.
 58. Peyron JG, Balazs EA. Preliminary clinical assessment of

- Nahyaluronate injection of the human knee. *Pathol Biol.* 1974;22:731-736.
59. Bagga H, Burkhardt D, Sambrook P, March L. Longterm effects of intraarticular hyaluronan on synovial fluid in osteoarthritis of the knee. *J Rheumatol.* 2006;33:946-950.
 60. Kusayama Y, Akamatsu Y, Kumagai K, Kobayashi H, Aratake M, Saito T. Changes in synovial fluid biomarkers and clinical efficacy of intra-articular injections of hyaluronic acid for patients with knee osteoarthritis. *J Exp Orthop.* 2014 Dec;1(1):16.
 61. Shimizu M, Higuchi H, Takagishi K, Shinozaki T, Kobayashi T. Clinical and biochemical characteristics after intra-articular injection for the treatment of osteoarthritis of the knee: prospective randomized study of sodium hyaluronate and corticosteroid. *J Orthop Sci.* 2010 Jan;15(1):51-56.
 62. Wiig M, Abrahamsson SO, Lundborg G. Effects of hyaluronan on cell proliferation and collagen synthesis: a study of rabbit flexor tendons in vitro. *J Hand Surg Am.* 1997;22:818-825.
 63. Tomonaga A, Hamada K, Gotoh M, Yamakawa H, Kobayashi K, Fukuda H. Expression of procollagen alpha 1 type III mRNA in rotator cuff tears. *Tokai J Exp Clin Med.* 2000;25(3):125-134.
 64. Osti L, Berardocco M, di Giacomo V, Di Bernardo G, Oliva F, Berardi AC. Hyaluronic acid increases tendon derived cell viability and collagen type I expression in vitro: Comparative study of four different Hyaluronic acid preparations by molecular weight. *BMC Musculoskelet Disord.* 2015;16(1):284.
 65. Halici M, Karaoglu S, Canoz O, Kabak S, Baktir A. Sodium hyaluronate regulating angiogenesis during Achilles tendon healing. *Knee Surg Sports Traumatol Arthrosc.* 2004;12(6):562-567.
 66. Goto M, Hanyu T, Yoshio T, et al. Intra-articular injection of hyaluronate (SI-6601D) improves joint pain and synovial fluid prostaglandin E2 levels in rheumatoid arthritis: a multicenter clinical trial. *Clin Exp Rheumatol.* 2001;19:377-383.
 67. Salamanna F, Frizziero A, Pagani S, et al. Metabolic and cytoprotective effects of in vivo peri-patellar hyaluronic acid injections in cultured tenocytes. *Connect Tissue Res.* 2015;56:35-43.
 68. Kumai T, Muneta T, Tsuchiya A, et al. The short-term effect after a single injection of high-molecular-weight hyaluronic acid in patients with enthesopathies (lateral epicondylitis, patellar tendinopathy, insertional Achilles tendinopathy, and plantar fasciitis): a preliminary study. *J Orthop Sci.* 2014;19(4):603-611.
 69. Huang MH, Yang RC, Chou PH. Preliminary effects of hyaluronic acid on early rehabilitation of patients with isolated anterior cruciate ligament reconstruction. *Clin J Sport Med.* 2007 Jul;17(4):242-250.
 70. Messina C, Banfi G, Orlandi D, et al. Ultrasound-guided interventional procedures around the shoulder. *Br J Radiol.* 2016;89(1057):20150372.
 71. Chen CP, Hsu CC, Pei YC. Changes of synovial fluid protein concentrations in supra-patellar bursitis patients after the injection of different molecular weights of hyaluronic acid. *Exp Gerontol.* 2014 Apr;52:30-35.
 72. Greving K, Dorrestijn O, Winters JC, Groenhof F, van der Meer K, Stevens M, et al. Incidence, prevalence, and consultation rates of shoulder complaints in general practice. *Scand J of Rheumatol.* 2012;41:150-155.
 73. Michener LA, McClure PW, Karduna AR. Anatomical and biomechanical mechanisms of subacromial impingement syndrome. *Clin Biomech (Bristol, Avon).* 2003;18:369-379.
 74. Tekavec E, Jöud A, Rittner R, Mikocz Z, Nordander C, Petersson IF, et al. Population-based consultation patterns in patients with shoulder pain diagnoses. *BMC Musculoskeletal Disorders.* 2012;13:238.
 75. Blaine T, Moskowitz R, Udell J, Skyhar M, Levin R, Friedlander J, et al. Treatment of persistent shoulder pain with sodium hyaluronate: a randomized, controlled trial. A multicenter study. *J Bone Joint Surg Am.* 2008;90:970-979.
 76. Kwon YW, Eisenberg G, Zuckerman JD. Sodium hyaluronate for the treatment of chronic shoulder pain associated with glenohumeral osteoarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. *J Shoulder Elbow Surg.* 2013;22:584-594.
 77. Merolla G, Sperling JW, Paladini P, Porcellini G. Efficacy of Hyilan G-F 20 versus 6-methylprednisolone acetate in painful shoulder osteoarthritis: a retrospective controlled trial. *Musculoskeletal Surgery.* 2011;95:215-224.
 78. Ozgen M, Firat S, Sarsan A, Topuz O, Ardic F, Baydemir C. Short- and long-term results of clinical effectiveness of sodium hyaluronate injection in supraspinatus tendinitis. *Rheumatol Int.* 2012;32:137-144.
 79. Costantino C, Olvirri S. Rehabilitative and infiltrative treatment with hyaluronic acid in elderly patients with rotator cuff tears. *Acta Bio-Medica: Atenei Parmensis.* 2009;80:225-229.
 80. Porcellini G, Merolla G, Giordan N, Paladini P, Burini A, Cesari E, et al. Intra-articular glenohumeral injections of HYADD®4-G for the treatment of painful shoulder osteoarthritis: a prospective multicenter, open-label trial. *Joints* 2016.;3:116-121.
 81. Brander VA, Gomberawalla A, Chambers M, Bowen M, Nuber G. Efficacy and safety of hylan G-F 20 for symptomatic glenohumeral osteoarthritis: a prospective, pilot study. *PM R.* 2010;2:259-267.
 82. Silverstein E, Leger R, Shea KP. The use of intra-articular hylan G-F 20 in the treatment of symptomatic osteoarthritis of the shoulder: a preliminary study. *Am J Sports Medicine.* 2007;35:979-985.
 83. Noël E, Hardy P, Hagen FW, Laprelle E, Goebel F, Faure C, et al. Efficacy and safety of Hyilan G-F 20 in shoulder osteoarthritis with an intact rotator cuff. Open-label prospective multicenter study. *Joint Bone Spine.* 2009;76:670-673.
 84. Park KD, Nam H-S, Lee JK, Kim YJ, Park Y. Treatment effects of ultrasound-guided capsular distension with hyaluronic acid in adhesive capsulitis of the shoulder. *Archives of Physical Medicine and Rehabilitation.* 2013;94:264-270.
 85. Porcellini G, Merolla G, Giordan N, Paladini P, Burini A, Cesari E, et al. Intra-articular glenohumeral injections of HYADD®4-G for the treatment of painful shoulder osteoarthritis: a prospective multicenter, open-label trial. *Joints n.d.*;3:116-121.
 86. Osti L, Buda M, Buono AD, Osti R, Massari L. Clinical evidence in the treatment of rotator cuff tears with hyaluronic acid. *MLTJ.* 2016 Feb 13;5(4):270-275.
 87. Itokazu M, Matsunaga T. Clinical evaluation of high-molecular-weight sodium hyaluronate for the treatment of patients with periarthritis of the shoulder. *Clin Ther.* 1995.;17:946-955.
 88. Tamai K, Mashitori H, Ohno W, Hamada J, Sakai H, Saotome K. Synovial response to intraarticular injections of hyaluronate in frozen shoulder: a quantitative assessment with dynamic magnetic resonance imaging. *J Orthop Sci: Official Journal of the Japanese Orthopaedic Association.* 2004;9:230-234.
 89. Rovetta G, Monteforte P. Intraarticular injection of sodium hyaluronate plus steroid versus steroid in adhesive capsulitis of the shoulder. *Intern J of Tissue Reactions.* 1998;20:125-130.
 90. Hsieh L-F, Hsu W-C, Lin Y-J, Chang H-L, Chen C-C, Huang V. Addition of intra-articular hyaluronate injection to physical therapy program produces no extra benefits in patients with adhesive capsulitis of the shoulder: a randomized controlled trial. *Arch of Phys Med Rehabil.* 2012;93:957-964.
 91. Meloni F, Milia F, Cavazzuti M, Doria C, Lisai P, Profili S, et al. Clinical evaluation of sodium hyaluronate in the treatment of patients with supraspinatus tendinosis under echographic guide: experimental study of periarthral injections. *Eur J Radiol.* 2008;68:170-173.
 92. Chou WY, Ko JY, Wang FS, Huang CC, Wong T, Wang C-J, et al. Effect of sodium hyaluronate treatment on rotator cuff lesions without complete tears: a randomized, double-blind,

- placebo-controlled study. *Journal of Shoulder and Elbow Surgery*. 2010;19:557-563.
93. Tagliafico A, Serafini G, Sconfienza LM, Lacelli F, Perrone N, Succio G, et al. Ultrasound-guided viscosupplementation of subacromial space in elderly patients with cuff tear arthropathy using a high weight hyaluronic acid: prospective open-label non-randomized trial. *Europ Radiol*. 2011;21:182-187.
 94. Petrella RJ, Cogliano A, Decaria J, Mohamed N, Lee R. Management of Tennis Elbow with sodium hyaluronate periarticular injections. *Sports Med Arthrosc Rehab Ther Technol*. 2010 Feb 2;2:4.
 95. Tosun HB, Gurmustas S, Agir I, Uludag A, Serbest S, Pepele D, Ertem K. Comparison of the effects of sodium hyaluronate-chondroitin sulphate and corticosteroid in the treatment of lateral epicondylitis: a prospective randomized trial. *J Orthop Sci*. 2015 Sep;20(5):837-843.
 96. van Brakel RW, Eygendaal D. Intra-articular injection of hyaluronic acid is not effective for the treatment of post-traumatic osteoarthritis of the elbow. *Arthroscopy*. 2006 Nov;22(11):1199-1203.
 97. Pederzini LA, Milandri L, Tosi M, Prandini M, Nicoletta F. Preliminary clinical experience with hyaluronan anti-adhesion gel in arthroscopic arthrolysis for posttraumatic elbow stiffness. *J Orthop Traumatol*. 2013 Jun;14(2):109-114
 98. Tikiz C, Unlü Z, Sener A, Efe M, Tüzün C. Comparison of the efficacy of lower and higher molecular weight viscosupplementation in the treatment of hip osteoarthritis. *Clin Rheumatol*. 2005;24(3):244-250.
 99. Qvistgaard E, Christensen R, Torp-Pedersen S, Biddal H. Intra-articular treatment of hip osteoarthritis: a randomized trial of hyaluronic acid, corticosteroid, and isotonic saline. *Osteoarthritis Cart*. 2006;14(2):163-170.
 100. Van der Bekerom MPJ, Rys B, Mulier M. Viscosupplementation in the hip: evaluation of hyaluronic acid formulations. *Acta Orthop Trauma Surg*. 2008;128(3):275-280.
 101. Richette P, Ravaud P, Conrozier T, Euller-Ziegler L, Mazières B, Maugar et al. Effect of hyaluronic acid in symptomatic hip osteoarthritis: a multicenter, randomized, placebo-controlled trial. *Arthritis Rheum*. 2009;60(3):824-830.
 102. Migliore A, Massafra U, Bizzi E, Vacca F, Martin-Martin S, Granata M, et al. Comparative, double-blind, controlled study of intra-articular hyaluronic acid (Hyalubrix) injections versus local anesthetic in osteoarthritis of the hip. *Arthritis Res Ther*. 2009;11(6):R183.
 103. Spitzer AI, Bockow BI, Brander VA, Yates JW, McCarter DK, Gudger GK, Haller S, Lake SL, Magilavy DB. Hylan G-F 20 improves hip osteoarthritis: a prospective, randomized study. *Phys Sports Med*. 2010;38(2):35-47.
 104. Atchia I, Kane D, Reed MR, Isaacs JD, Birrell F. Efficacy of a single ultrasound-guided injection for the treatment of hip osteoarthritis. *Ann Rheum Dis*. 2011;70(1):110-116.
 105. Battaglia M, Guaraldi F, Vannini F, Rossi G, Timoncini A, Buda R, Giannini S. Efficacy of ultrasound-guided intra-articular injections of platelet-rich plasma versus hyaluronic acid for hip osteoarthritis. *Orthopedics*. 2013 Dec;36(12):e1501-8.
 106. Piccirilli E, Oliva F, Murè MA, Mahmoud A, Foti C, Tarantino U, Maffulli N. Viscosupplementation with intra-articular hyaluronic acid for hip disorders. A systematic review and meta-analysis. *MLTJ*. 2016 Dec 21;6(3):293-299.
 107. Waddell DD. Viscosupplementation with hyaluronans for osteoarthritis of the knee: clinical efficacy and economic implications. *Drugs Aging*. 2007;24(8):629-642.
 108. Day R, Brooks P, Conaghan PG, Petersen M. Multicenter Trial Group. A double blind, randomized, multicenter, parallel group study of the effectiveness and tolerance of intraarticular hyaluronan in osteoarthritis of the knee. *J Rheumatol*. 2004;31(4):775-782.
 109. Bannuru RR, Natov NS, Dasi UR, Schmid CH, McAlindon TE. Therapeutic trajectory following intra-articular hyaluronic acid injection in knee osteoarthritis-meta-analysis. *Osteoarthritis Cartilage*. 2011;19(6):611-619.
 110. Trigkilidas D & Anand A. The effectiveness of hyaluronic acid intra-articular injections in managing osteoarthritic knee pain. *Ann R Coll Surg Engl*. 2013;95(8):545-551.
 111. Strand V, McIntyre LF, Beach WR, Miller LE, Block JE. Safety and efficacy of US-approved viscosupplements for knee osteoarthritis: a systematic review and meta-analysis of randomized, saline-controlled trials. *J Pain Res*. 2015;8:217-228.
 112. Zhao H, Liu H, Liang X, Li Y, Wang J, Liu C. Hylan G-F 20 Versus Low Molecular Weight Hyaluronic Acids for Knee Osteoarthritis: A Meta-Analysis. *Bio Drugs*. 2016;30(5):387-396.
 113. Frizziero L, Govoni E, Bacchini P. Intra-articular hyaluronic acid in the treatment of osteoarthritis of the knee: clinical and morphological study. *Clin Exp Rheumatol*. 1998;16:441-449.
 114. Navarro-Sarabia F, Coronel P, Collantes E, Navarro FJ, de la Serna AR, Naranjo A, et al. AMELIA study group. A 40-month multicentre, randomised placebo-controlled study to assess the efficacy and carry-over effect of repeated intra-articular injections of hyaluronic acid in knee osteoarthritis: the AMELIA project. *Ann Rheum Dis*. 2011;70(11):1957-1962.
 115. Pasquali Ronchetti I, Guerra D, Taparelli F, Boraldi F, Bergamini G, Mori G, et al. Morphological analysis of knee synovial membrane biopsies from a randomized controlled clinical study comparing the effects of sodium hyaluronate (Hyalgan) and methylprednisolone acetate (Depomedrol) in osteoarthritis. *Rheumatology*. 2001;40:158-169.
 116. Guidolin DD, Ronchetti IP, Lini E, Guerra D, Frizziero L. Morphological analysis of articular cartilage biopsies from a randomized, clinical study comparing the effects of 500-730 kDa sodium hyaluronate (Hyalgan) and methylprednisolone acetate on primary osteoarthritis of the knee. *Osteoarthritis Cartilage*. 2001;9:371-381.
 117. Turajane T, Amphansap T, Labpiboonpong V, Maungsiri S. Total knee replacement following repeated cycles of intra-articular sodium hyaluronate (500-730 Kda) in failed conservative treatment of knee osteoarthritis: a 54-month follow-up. *J Med Assoc Thai*. 2009;92(Suppl 6):S63-S68.
 118. Waddell DD, Joseph B. Delayed Total Knee Replacement with Hylan G-F 20. *J Knee Surg*. 2016;29(2):159-168.
 119. Neustadt DH. Long-term efficacy and safety of intra-articular sodium hyaluronate (Hyalgan) in patients with osteoarthritis of the knee. *Clin Exp Rheumatol*. 2003;21(3):307-311.
 120. Whitman C, Allen D, Comadoll JL, Thomason HC, Oweida SJ. A retrospective study of Supartz and repeat treatment for osteoarthritis pain in the knee. *J Manag Care Med*. 2010;13(1):43-47.
 121. Sun SF, Chou YJ, Hsu CW, Chen WL. Hyaluronic acid as a treatment for ankle osteoarthritis. *Curr Rev Musculoskelet Med*. 2009;2(2):78-82.
 122. Witteveen AGH, Sierevelt IN, Blankevoort L, Kerkhoffs GMMJ, van Dijk CN. Intra-articular sodium hyaluronate injections in the osteoarthritic ankle joint: effects, safety and dose dependency. *Foot Ankle Surg Off J Eur Soc Foot Ankle Surg*. 2010;16(4):159-163.
 123. Salk RS, Chang TJ, D'Costa WF, Soomekh DJ, Grogan KA. Sodium hyaluronate in the treatment of osteoarthritis of the ankle: a controlled, randomized, double-blind pilot study. *J Bone Joint Surg Am*. 2006;88(2):295-302.
 124. Cohen MM, Altman RD, Hollstrom R, Hollstrom C, Sun C, Gipsen B. Safety and efficacy of intra-articular sodium hyaluronate (Hyalgan) in a randomized, double-blind study for osteoarthritis of the ankle. *Foot Ankle Int*. 2008;29(7):657-663.
 125. Karatosun V, Unver B, Ozden A, Ozay Z, Gunal I. Intra-articular hyaluronic acid compared to exercise therapy in osteoarthritis of the ankle. A prospective randomized trial with long-term follow-up. *Clin Exp Rheumatol*. 2008;26(2):288-294.

126. Carpenter B, Motley T. The role of viscosupplementation in the ankle using hylan G-F 20. *J Foot Ankle Surg.* 2008;47(5):377-384.
127. Mei-Dan O, Carmont MR, Laver L, Mann G, Maffulli N, Nyska M. Platelet-rich plasma or hyaluronate in the management of osteochondral lesions of the talus. *Am J Sports Med.* 2012; 40(3):534-541.
128. DeGroot H, Uzunishvili S, Weir R, Al-omari A, Gomes B. Intra-articular injection of hyaluronic acid is not superior to saline solution injection for ankle arthritis: a randomized, double-blind, placebo-controlled study. *J Bone Joint Surg Am.* 2012;94(1):2-8.
129. Sun SF, Hsu CW, Lin HS, Chou YJ, Chen JY, Wang JL. Efficacy of intraarticular botulinum toxin A and intraarticular hyaluronate plus rehabilitation exercise in patients with unilateral ankle osteoarthritis: a randomized controlled trial. *J Foot Ankle Res.* 2014;7(1):9.
130. Figen Ayhan F, Ustün N. The evaluation of efficacy and tolerability of Hylan G-F 20 in bilateral thumb base osteoarthritis: 6 months follow-up. *Clin Rheumatol.* 2009 May;28(5):535-541.
131. Salini V, De Amicis D, Abate M, Natale MA, Di Iorio A. Ultrasound-guided hyaluronic acid injection in carpometacarpal osteoarthritis: short-term results. *Int J Immunopathol Pharmacol.* 2009;22(2):455-460.
132. Di Sante L, Cacchio A, Scettri P, Paoloni M, Ioppolo F, Santilli V. Ultrasound-guided procedure for the treatment of trapeziometacarpal osteoarthritis. *Clin Rheumatol.* 2011 Sep;30(9): 1195-1200.
133. Frizziero A, Maffulli N, Masiero S, Frizziero L. Six-months pain relief and functional recovery after intra-articular injections with hyaluronic acid (mw 500-730 KDa) in trapeziometacarpal osteoarthritis. *MLTJ.* 2014 Jul 14;4(2):256-261.
134. Roux C, Fontas E, Breuil V, Brocq O, Albert C, Euler-Ziegler L. Injection of intra-articular sodium hyaluronate (Sinovial) into the carpometacarpal joint of the thumb (CMC1) in osteoarthritis. A prospective evaluation of efficacy. *Joint Bone Spine.* 2007 Jul;74(4):368-372.
135. Heyworth BE, Lee JH, Kim PD, Lipton CB, Strauch RJ, Rosenwasser MP. Hylan versus corticosteroid versus placebo for treatment of basal joint arthritis: a prospective, randomized, double-blinded clinical trial. *J Hand Surg Am.* 2008 Jan;33(1): 40-48.
136. Fuchs S, Mönikes R, Wohlmeiner A, Heyse T. Intra-articular hyaluronic acid compared with corticoid injections for the treatment of rhizarthrosis. *Osteoarthritis Cartilage.* 2006 Jan;14(1): 82-88.
137. Ingegnoli F, Soldi A, Meroni PL. Power Doppler sonography and clinical monitoring for hyaluronic Acid treatment of rhizarthrosis: a pilot study. *J Hand Microsurg.* 2011 Dec;3(2): 51-54.
138. Bahadır C, Onal B, Dayan VY, Güreş N. Comparison of therapeutic effects of sodium hyaluronate and corticosteroid injections on trapeziometacarpal joint osteoarthritis. *Clin Rheumatol.* 2009 May;28(5):529-533.
139. Stahl S, Karsh-Zafir I, Ratzon N, Rosenberg N. Comparison of intraarticular injection of depot corticosteroid and hyaluronic acid for treatment of degenerative trapeziometacarpal joints. *J Clin Rheumatol.* 2005 Dec;11(6):299-302.
140. Munteanu SE, Zammit GV, Menz HB, Landorf KB, Handley CJ, Elzarka A, Deluca J. Effectiveness of intra-articular hyaluronan (Synvisc, hylan G-F 20) for the treatment of first metatarsophalangeal joint osteoarthritis: a randomised placebo-controlled trial. *Ann Rheum Dis.* 2011 Oct;70(10):1838-1841.
141. Pons M, Alvarez F, Solana J, Viladot R, Varela L. Sodium hyaluronate in the treatment of hallux rigidus. A single-blind, randomized study. *Foot Ankle Int.* 2007 Jan;28(1):38-42.
142. Petrella RJ, Cogliano A. Intra-articular Hyaluronic Acid Treatment for Golfer's Toe: Keeping Older Golfers on Course. *Phys Sportsmed.* 2004 Jul;32(7):41-45.
143. Wiig ME, Dahlin LB, Fridén J, Hagberg L, Larsen SE, Wiklund K, Mahlapuu M. PXL01 in sodium hyaluronate for improvement of hand recovery after flexor tendon repair surgery: randomized controlled trial. *PLoS One.* 2014 Oct 23;9(10): e110735.
144. Ozgenel GY, Etöz A. Effects of repetitive injections of hyaluronic acid on peritendinous adhesions after flexor tendon repair: a preliminary randomized, placebo-controlled clinical trial. *Ulus Travma Acil Cerrahi Derg.* 2012 Jan;18(1):11-17.
145. Riccio M, Battiston B, Pajardi G, Corradi M, Passarelli U, Atzei A, et al. Study Group on Tendon Adhesion of Italian Society of Hand Surgery. Efficiency of Hyaloglide in the prevention of the recurrence of adhesions after tenolysis of flexor tendons in zone II: a randomized, controlled, multicentre clinical trial. *J Hand Surg Eur Vol.* 2010 Feb;35(2):130-138.
146. Hagberg L. Exogenous hyaluronate as an adjunct in the prevention of adhesions after flexor tendon surgery: a controlled clinical trial. *J Hand Surg Am.* 1992 Jan;17(1):132-136.
147. Liu DH, Tsai MW, Lin SH, Chou CL, Chiu JW, Chiang CC, Kao CL. Ultrasound-Guided Hyaluronic Acid Injections for Trigger Finger: A Double-Blinded, Randomized Controlled Trial. *Arch Phys Med Rehabil.* 2015 Dec;96(12):2120-2127.
148. Callegari L, Spanò E, Bini A, Valli F, Genovese E, Fugazzola C. Ultrasound-guided injection of a corticosteroid and hyaluronic acid: a potential new approach to the treatment of trigger finger. *Drugs R D.* 2011;11(2):137-145.
149. Tosun HB, Gumustas S, Agir I, Uludag A, Serbest S, Pepele D, Ertem K. Comparison of the effects of sodium hyaluronate-chondroitin sulphate and corticosteroid in the treatment of lateral epicondylitis: a prospective randomized trial. *J Orthop Sci.* 2015 Sep;20(5):837-843.
150. Muneta T, Koga H, Ju YJ, Mochizuki T, Sekiya I. Hyaluronan injection therapy for athletic patients with patellar tendinopathy. *J Orthop Sci.* 2012 Jul;17(4):425-431.
151. Chang WH, Im SH, Ryu JA, Lee SC, Kim JS. The effects of scapulothoracic bursa injections in patients with scapular pain: a pilot study. *Arch Phys Med Rehabil.* 2009 Feb;90(2):279-284.
152. Chen CP, Hsu CC, Pei YC, Chen RL, Zhou S, Shen HC, et al. Changes of synovial fluid protein concentrations in supra-patellar bursitis patients after the injection of different molecular weights of hyaluronic acid. *Exp Gerontol.* 2014 Apr;52:30-35.
153. de Campos GC, Rezende MU, Pailo AF, Frucchi R, Camargo OP. Adding triamcinolone improves viscosupplementation: a randomized clinical trial. *Clin Orthop Relat Res.* 2013 Feb;471(2):613-620.
154. Giraddi GB, Siddaraju A, Kumar A, Jain T. Comparison Between Betamethasone and Sodium Hyaluronate Combination with Betamethasone Alone After Arthrocentesis in the Treatment of Internal Derangement of TMJ-Using Single Puncture Technique: A Preliminary Study. *J Maxillofac Oral Surg.* 2015 Jun;14(2):403-409.
155. Ozturk C, Atamaz F, Hepguler S, Argin M, Arkun R. The safety and efficacy of intraarticular hyaluronan with/without corticosteroid in knee osteoarthritis: 1-year, single-blind, randomized study. *Rheumatol Int.* 2006 Feb;26(4):314-319.
156. Petrella RJ, Emans PJ, Alleyne J, Dellaert F, Gill DP, Maroney M. Safety and performance of Hydros and Hydros-TA for knee osteoarthritis: a prospective, multicenter, randomized, double-blind feasibility trial. *BMC Musculoskelet Disord.* 2015 Mar 18;16:57.
157. Briggs KK, Matheny LM, Steadman JR. Can Hylan G-F 20 with corticosteroid meet the expectations of osteoarthritis patients? *Am J Orthop (Belle Mead NJ).* 2012 Jul;41(7):311-315.
158. Lee SC, Rha DW, Chang WH. Rapid analgesic onset of intra-articular hyaluronic acid with ketorolac in osteoarthritis of the

- knee. *J Back Musculoskelet Rehabil.* 2011;24(1):31-38.
159. Palmieri B, Rottigni V, Iannitti T. Preliminary study of highly cross-linked hyaluronic acid-based combination therapy for management of knee osteoarthritis-related pain. *Drug Des Devel Ther.* 2013;7:7-12.
 160. Saturveithan C, Premganes G, Fakhrizaki S, Mahathir M, Karuna K, Rauf K, et al. Intra-articular Hyaluronic Acid (HA) and Platelet Rich Plasma (PRP) injection versus Hyaluronic acid (HA) injection alone in Patients with Grade III and IV Knee Osteoarthritis (OA): A Retrospective Study on Functional Outcome. *Malays Orthop J.* 2016;10(2).
 161. Saw KY, Anz A, Siew-Yoke Jee C, Merican S, Ching-Soong Ng R, Roohi SA, Ragavanaidu K. Articular cartilage regeneration with autologous peripheral blood stem cells versus hyaluronic acid: a randomized controlled trial. *Arthroscopy.* 2013 Apr;29(4):684-694.
 162. Giombini A, Menotti F, Di Cesare A, Giovannangeli F, Rizzo M, Moffa F, Martinelli F. Comparison between intrarticular injection of hyaluronic acid, oxygen ozone, and the combination of both in the treatment of knee osteoarthritis. *J Biol Regul Homeost Agents.* 2016 Apr-Jun;30(2):621-625.
 163. Conrozier T, Bozgan AM, Bossert M, Sondag M, Lohse-Walliser A, Balblanc JC. Standardized Follow-up of Patients with Symptomatic Knee Osteoarthritis Treated with a Single Intra-articular Injection of a Combination of Cross-Linked Hyaluronic Acid and Mannitol. *Clin Med Insights Arthritis Musculoskelet Disord.* 2016 Sep 25;9:175-179.
 164. Henrotin Y, Hauzeur JP, Bruel P, Appelboom T. Intra-articular use of a medical device composed of hyaluronic acid and chondroitin sulfate (Structovial CS): effects on clinical, ultrasonographic and biological parameters. *BMC Res Notes.* 2012 Aug 4;5:407.
 165. Lee HJ, Lim KB, Kim DY, Lee KT. Randomized controlled trial for efficacy of intra-articular injection for adhesive capsulitis: ultrasonography-guided versus blind technique. *Arch Phys Med Rehabil.* 2009 Dec; 90(12):1997-2002.
 166. Kim YS, Park JY, Lee CS, Lee SJ. Does hyaluronate injection work in shoulder disease in early stage? A multicenter, randomized, single blind and open comparative clinical study. *J Shoulder Elbow Surg.* 2012 Jun;21(6):722-727.
 167. Orlandi D, Corazza A, Fabbro E, Ferrero G, Sabino G, Serafini G, et al. Ultrasound-guided percutaneous injection to treat de Quervain's disease using three different techniques: a randomized controlled trial. *Eur Radiol.* 2015 May;25(5):1512-1519.
 168. Monfort J, Rotés-Sala D, Segalés N, Montañés FJ, Orellana C, Llorente-Onaindia J, et al. Comparative efficacy of intra-articular hyaluronic acid and corticoid injections in osteoarthritis of the first carpometacarpal joint: results of a 6-month single-masked randomized study. *Joint Bone Spine.* 2015 Mar;82(2): 116-121.
 169. Bum Park Y, Ah Choi W, Kim YK, Chul Lee S, Hae Lee J. Accuracy of blind versus ultrasound-guided suprapatellar bursal injection. *J Clin Ultrasound.* 2012 Jan;40(1):20-25.
 170. Karatosun V, Unver B, Gocen Z, Sen A, Gunal I. Intra-articular hyaluronic acid compared with progressive knee exercises in osteoarthritis of the knee: a prospective randomized trial with long-term follow-up. *Rheumatol Int.* 2006 Feb;26(4):277-284.
 171. Kawasaki T, Kurosawa H, Ikeda H, Takazawa Y, Ishijima M, Kubota M, et al. Therapeutic home exercise versus intra-articular hyaluronate injection for osteoarthritis of the knee: 6-month prospective randomized open-labeled trial. *J Orthop Sci.* 2009 Mar;14(2):182-191.
 172. Saccomanno MF, Donati F, Careri S, Bartoli M, Severini G, Milano G. Efficacy of intra-articular hyaluronic acid injections and exercise-based rehabilitation programme, administered as isolated or integrated therapeutic regimens for the treatment of knee osteoarthritis. *Knee Surg Sports Traumatol Arthrosc.* 2016 May;24(5):1686-1694.
 173. Monticone M, Frizziero A, Rovere G, Vittadini F, Uliano D, La Bruna S, et al. Hyaluronic acid intra-articular injection and exercise therapy: effects on pain and disability in subjects affected by lower limb joints osteoarthritis. A systematic review by the Italian Society of Physical and Rehabilitation Medicine (SIMFER). *Eur J Phys Rehabil Med.* 2016 Jun;52(3):389-399.
 174. Di Giacomo G, De Gasperis N. The role of hyaluronic acid in patients affected by glenohumeral osteoarthritis. *J Biol Regul Homeost Agents.* 2015 Oct-Dec;29(4):945-951.
 175. Huang MH, Yang RC, Lee CL, Chen TW, Wang MC. Preliminary results of integrated therapy for patients with knee osteoarthritis. *Arthritis Rheum.* 2005;53:812-820.
 176. Ip D, Fu NY. Can combined use of low-level lasers and hyaluronic acid injections prolong the longevity of degenerative knee joints? *Clin Interv Aging.* 2015 Aug 5;10:1255-1258.
 177. Bayramoğlu M, Karataş M, Cetin N, Akman N, Sözüy S, Dilek A. Comparison of two different viscosupplements in knee osteoarthritis: a pilot study. *Clin Rheumatol.* 2003 May;22(2):118-122.
 178. Mathies B. Effects of Viscoseal, a synovial fluid substitute, on recovery after arthroscopic partial meniscectomy and joint lavage. *Knee Surg Sports Traumatol Arthrosc.* 2006;14:32-39.
 179. Thein R, Haviv B, Kidron A, Bronak S. Intra-articular injection of hyaluronic acid following arthroscopic partial meniscectomy of the knee. *Orthopedics.* 2010;33:724.
 180. Filardo G, Di Matteo B, Tentoni F, et al. No Effects of Early Viscosupplementation After Arthroscopic Partial Meniscectomy: A Randomized Controlled Trial. *Am J Sports Med.* 2016;44(12):3119-3125.
 181. Chau J, Chan WL, Woo SB. Hyaluronic acid instillation following arthroscopic anterior cruciate ligament reconstruction: a double-blinded, randomized controlled study. *Journal of Orthop Surg.* 2012;20:162-165.
 182. Di Martino A, Tentoni F, Di Matteo B, et al. Early Viscosupplementation After Anterior Cruciate Ligament Reconstruction: A Randomized Controlled Trial. *Am J Sport Med.* 2016.
 183. Heybeli N, Doral MN, Atay OA, Leblebicioglu G, Uzumcugil A. Intra-articular sodium hyaluronate injections after arthroscopic debridement for osteoarthritis of the knee: a prospective, randomized, controlled study. *Acta Orthop Traumatol Turc.* 2008;42:221-227.
 184. Westrich G, Schaefer S, Walcott-Sapp S, et al. Randomized prospective evaluation of adjuvant hyaluronic acid therapy administered after knee arthroscopy. *Am J Orthop (Belle Mead NJ).* 2009;38:612-616.
 185. Hempfling H. Intra-articular hyaluronic acid after knee arthroscopy: a two-year study. *Knee Surg Sports Traumatol Arthrosc.* 2007;15:537-546.
 186. Oh CH, Oh JH, Kim SH, Cho JH, Yoon JP, Kim JY. Effectiveness of subacromial anti-adhesive agent injection after arthroscopic rotator cuff repair: prospective randomized comparison study. *Clin in Orthop Surg.* 2011;3:55-61.
 187. Doral MN, Bilge O, Batmaz G, et al. Treatment of osteochondral lesions of the talus with microfracture technique and post-operative hyaluronan injection. *Knee Surg Sports Traumatol Arthrosc.* 2012;20:1398-1403.
 188. Görmeli G, Karakaplan M, Görmeli CA, Sarıkaya B, Elmalı N, Ersoy Y. Clinical Effects of Platelet-Rich Plasma and Hyaluronic Acid as an Additional Therapy for Talar Osteochondral Lesions Treated with Microfracture Surgery: A Prospective Randomized Clinical Trial. *Foot Ankle Int.* 2015;36:891-900.
 189. Abate M, Pelotti P, De Amicis D, Di Iorio A, Galletti S, Salini V. Viscosupplementation with hyaluronic acid in hip osteoarthritis (a review). *Ups J Med Sci.* 2008;113(3):261-277.
 190. Shi Z, Guo C, Awad M. Hyaluronate for temporomandibular joint disorders. *Cochrane Database Syst Rev.* 2003;(1):

- CD002970.
191. Saito S, Furuya T, Kotake S. Therapeutic effects of hyaluronate injections in patients with chronic painful shoulder: a meta-analysis of randomized controlled trials. *Arthritis Care Res (Hoboken)*. 2010 Jul;62(7):1009-1018.
 192. Altman RD, Moskowitz R. Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. *Hyalgan Study Group. J Rheumatol*. 1998 Nov;25(11):2203-2212.
 193. Altman RD, Rosen JE, Bloch DA, Hatoum HT, Korner P. A double-blind, randomized, saline-controlled study of the efficacy and safety of EUFLEXA for treatment of painful osteoarthritis of the knee, with an open-label safety extension (the FLEXX trial). *Semin Arthritis Rheum*. 2009 Aug;39(1):1-9.
 194. Altman RD, Rosen JE, Bloch DA, Hatoum HT. Safety and efficacy of retreatment with a bioengineered hyaluronate for painful osteoarthritis of the knee: results of the open-label Extension Study of the FLEXX Trial. *Osteoarthritis Cartilage*. 2011 Oct;19(10):1169-1175.
 195. Arden NK, Åkermark C, Andersson M, Todman MG, Altman RD. A randomized saline-controlled trial of NASHA hyaluronic acid for knee osteoarthritis. *Curr Med Res Opin*. 2014 Feb;30(2):279-286.
 196. Arrich J, Piribauer F, Mad P, Schmid D, Klaushofer K, Müllner M. Intra-articular hyaluronic acid for the treatment of osteoarthritis of the knee: systematic review and meta-analysis. *CMAJ*. 2005 Apr 12;172(8):1039-1043.
 197. Bannuru RR, Vaysbrot EE, Sullivan MC, McAlindon TE. Relative efficacy of hyaluronic acid in comparison with NSAIDs for knee osteoarthritis: a systematic review and meta-analysis. *Semin Arthritis Rheum*. 2014 Apr;43(5):593-599.
 198. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Viscosupplementation for the treatment of osteoarthritis of the knee. *Cochrane Database Syst Rev*. 2005 Apr 18;(2):CD005321.
 199. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Viscosupplementation for the treatment of osteoarthritis of the knee. *Cochrane Database Syst Rev*. 2006 Apr 19;(2):CD005321.
 200. Brandt KD, Block JA, Michalski JP, Moreland LW, Caldwell JR, Lavin PT. Efficacy and safety of intraarticular sodium hyaluronate in knee osteoarthritis. *ORTHOVISC Study Group. Clin Orthop Relat Res*. 2001 Apr;(385):130-143.
 201. Brzusek D, Petron D. Treating knee osteoarthritis with intra-articular hyaluronans. *Curr Med Res Opin*. 2008 Dec;24(12):3307-3322.
 202. Chevalier X, Jerosch J, Goupille P, van Dijk N, Luyten FP, Scott DL, et al. Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial. *Ann Rheum Dis*. 2010 Jan;69(1):113-119.
 203. Espallargues M, Pons JM. Efficacy and safety of viscosupplementation with Hylan G-F 20 for the treatment of knee osteoarthritis: a systematic review. *Int J Technol Assess Health Care*. 2003 Winter;19(1):41-56.
 204. Filardo G, Kon E, Di Martino A, Di Matteo B, Merli ML, Cenacchi A, et al. Platelet-rich plasma vs hyaluronic acid to treat knee degenerative pathology: study design and preliminary results of a randomized controlled trial. *BMC Musculoskelet Disord*. 2012 Nov 23;13:229.
 205. Jørgensen A, Stengaard-Pedersen K, Simonsen O, Pfeiffer-Jensen M, Eriksen C, Bliddal H, et al. Intra-articular hyaluronan is without clinical effect in knee osteoarthritis: a multicentre, randomised, placebo-controlled, double-blind study of 337 patients followed for 1 year. *Ann Rheum Dis*. 2010 Jun;69(6):1097-1102.
 206. Lee PB, Kim YC, Lim YJ, Lee CJ, Sim WS, Ha CW, et al. Comparison between high and low molecular weight hyaluronates in knee osteoarthritis patients: open-label, randomized, multicentre clinical trial. *J Int Med Res*. 2006 Jan-Feb;34(1):77-87.
 207. Leighton R, Åkermark C, Therrien R, Richardson JB, Anderson M, Todman MG, Arden NK. NASHA hyaluronic acid vs methylprednisolone for knee osteoarthritis: a prospective, multi-centre, randomized, non-inferiority trial. *Osteoarthritis Cartilage*. 2014 Jan;22(1):17-25.
 208. Maheu E, Zaim M, Appelboom T, Jeka S, Trc T, Berenbaum F, et al. Comparative efficacy and safety of two different molecular weight (MW) hyaluronans F60027 and Hylan G-F20 in symptomatic osteoarthritis of the knee (KOA). Results of a non inferiority, prospective, randomized, controlled trial. *Clin Exp Rheumatol*. 2011 May-Jun;29(3):527-535.
 209. Neustadt D, Caldwell J, Bell M, Wade J, Gimbel J. Clinical effects of intraarticular injection of high molecular weight hyaluronan (Orthovisc) in osteoarthritis of the knee: a randomized, controlled, multicenter trial. *J Rheumatol*. 2005 Oct;32(10):1928-1936.
 210. Petrella RJ, Petrella M. A prospective, randomized, double-blind, placebo controlled study to evaluate the efficacy of intraarticular hyaluronic acid for osteoarthritis of the knee. *J Rheumatol*. 2006 May;33(5):951-956.
 211. Reichenbach S, Blank S, Rutjes AW, Shang A, King EA, Dieppe PA, et al. Hylan versus hyaluronic acid for osteoarthritis of the knee: a systematic review and meta-analysis. *Arthritis Rheum*. 2007 Dec 15;57(8):1410-1418.
 212. Saito S, Kotake S. Is there evidence in support of the use of intra-articular hyaluronate in treating rheumatoid arthritis of the knee? A meta-analysis of the published literature. *Mod Rheumatol*. 2009;19(5):493-501.
 213. Wang CT, Lin J, Chang CJ, Lin YT, Hou SM. Therapeutic effects of hyaluronic acid on osteoarthritis of the knee. A meta-analysis of randomized controlled trials. *J Bone Joint Surg Am*. 2004 Mar;86-A(3):538-545.
 214. Wobig M, Bach G, Beks P, Dickhut A, Runzheimer J, Schwieger G, et al. The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: a comparison of hylan G-F 20 and a lower-molecular-weight hyaluronan. *Clin Ther*. 1999 Sep;21(9):1549-1562.
 215. Yu FF, Xia CT, Fang H, Han J, Younus MI, Guo X. Evaluation of the therapeutic effect of treatment with intra-articular hyaluronic acid in knees for Kashin-Beck disease: a meta-analysis. *Osteoarthritis Cartilage*. 2014 Jun;22(6):718-725.
 216. Chang KV, Hsiao MY, Chen WS, Wang TG, Chien KL. Effectiveness of intra-articular hyaluronic acid for ankle osteoarthritis treatment: a systematic review and meta-analysis. *Arch Phys Med Rehabil*. 2013 May;94(5):951-960.
 217. Wobig M, Dickhut A, Maier R, Vetter G. Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. *Clin Ther*. 1998 May-Jun;20(3):410-423.
 218. Ishijima M, Nakamura T, Shimizu K, Hayashi K, Kikuchi H, Soen S, et al. Intra-articular hyaluronic acid injection versus oral non-steroidal anti-inflammatory drug for the treatment of knee osteoarthritis: a multi-center, randomized, open-label, non-inferiority trial. *Arthritis Res Ther*. 2014 Jan 21;16(1):R18.
 219. Jüni P, Reichenbach S, Trelle S, Tschannen B, Wandel S, Jordi B, et al. Efficacy and safety of intraarticular hylan or hyaluronic acids for osteoarthritis of the knee: a randomized controlled trial. *Arthritis Rheum*. 2007 Nov;56(11):3610-3619.
 220. Medina JM, Thomas A, Denegar CR. Knee osteoarthritis: should your patient opt for hyaluronic acid injection? *J Fam Pract*. 2006 Aug;55(8):669-675.
 221. Tang X, Pei FX, Zhou ZK, Liu G, Shen B, Kang PD, et al. A randomized, single-blind comparison of the efficacy and tolerability of hyaluronate acid and meloxicam in adult patients with Kashin-Beck disease of the knee. *Clin Rheumatol*. 2012 Jul;31(7):1079-1086.

222. Diracoglu D, Vural M, Baskent A, Dikici F, Aksoy C. The effect of viscosupplementation on neuromuscular control of the knee in patients with osteoarthritis. *J Back Musculoskelet Rehabil.* 2009;22(1):1-9.
223. Fuchs S, Erbe T, Fischer HL, Tibesku CO. Intraarticular hyaluronic acid versus glucocorticoid injections for nonradicular pain in the lumbar spine. *J Vasc Interv Radiol.* 2005 Nov; 16(11):1493-1498.
224. Fernández López JC, Ruano-Ravina A. Efficacy and safety of intraarticular hyaluronic acid in the treatment of hip osteoarthritis: a systematic review. *Osteoarthritis Cartilage.* 2006 Dec;14(12):1306-1311.
225. Lundsgaard C, Dufour N, Fallentin E, Winkel P, Gluud C. Intra-articular sodium hyaluronate 2 mL versus physiological saline 20 mL versus physiological saline 2 mL for painful knee osteoarthritis: a randomized clinical trial. *Scand J Rheumatol.* 2008 Mar-Apr;37(2):142-150.
226. Oliveras-Moreno JM, Hernandez-Pacheco E, Oliveras-Quintana T, Infante-Cossio P, Gutierrez-Perez JL. Efficacy and safety of sodium hyaluronate in the treatment of Wilkes stage II disease. *J Oral Maxillofac Surg.* 2008 Nov;66(11):2243-2246.
227. Strand V, Baraf HS, Lavin PT, Lim S, Hosokawa H. A multicenter, randomized controlled trial comparing a single intra-articular injection of Gel-200, a new cross-linked formulation of hyaluronic acid, to phosphate buffered saline for treatment of osteoarthritis of the knee. *Osteoarthritis Cartilage.* 2012 May;20(5):350-356.